# Recent Advances in the Design and Development of Novel Negative Allosteric Modulators of mGlu₅

Kyle A. Emmitte

Department of Pharmacology, Vanderbilt Center for Neuroscience Drug Discovery, and Department of Chemistry, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States

ABSTRACT: Negative allosteric modulators (NAMs) of metabotropic glutamate receptor subtype 5 (mGlu₅) have remained attractive to researchers as potential therapies for a number of central nervous system related diseases, including anxiety, pain, gastresophageal reflux disease (GERD), addiction, Parkinson's disease (PD), and fragile X syndrome (FXS). In addition to the many publications with supportive preclinical data with key tool molecules, recent positive reports from the clinic have bolstered the confidence in this approach. During the 2 year time span from 2009 through 2010, a number of new mGlu₅ NAM chemotypes have been disclosed and discussed in the primary and patent literature. A summary of several efforts representing many diverse chemotypes are presented here, along with a discussion of representative structure—activity relationships (SAR) and synthetic approaches to the templates where possible.

KEYWORDS: Metabotropic glutamate receptor 5, negative allosteric modulator, anxiety, pain, gastresophageal reflux disease, addiction, Parkinson's disease, fragile X syndrome

Glutamate (L-glutamic acid), the major excitatory transmitter in the mammalian central nervous system (CNS), exerts its effects through both ionotropic and metabotropic glutamate receptors, thereby generating the fast excitatory synaptic responses at the majority of CNS synapses. While ionotropic glutamate receptors are ligand-gated ion channels responsible for mediation of glutamate fast transmission, the metabotropic glutamate receptors (mGlus) belong to family C of the G-protein-coupled receptors (GPCRs) and modulate the strength of synaptic transmission. The mGlus are characterized by a seven transmembrane (7TM) α-helical domain connected via a cysteine rich-region to a large bilobed extracellular amino-terminal domain. While the orthosteric binding site is contained in the amino-terminal domain, currently known allosteric binding sites reside in the 7TM domain. The eight mGlus discovered to date have been divided according to their structure, preferred signal transduction mechanisms, and pharmacology (group I: mGlu₁ and mGlu₅; group II: mGlu₂ and mGlu₃; group III: mGlu₄, mGlu₆, mGlu₇, and mGlu₈). Group I mGlus are located postsynaptically and are coupled via G_q to the activation of phospholipase C, which leads to the elevation of intracellular calcium (Ca^{2+}) and activation of protein kinase C (PKC). Both group II and group III mGlus are located presynaptically and are coupled via G_i/G_o to the inhibition of adenylyl cylase activity.[1,2]

The mGlus have long been considered attractive therapeutic targets for a variety of neurological and psychiatric disorders. As such, several small molecule mGlu agonists and antagonists that compete with glutamate for the orthosteric binding site have been developed and studied.[3] Still, selectively targeting a specific mGlu through the use of an orthosteric ligand has proven difficult due to the highly conserved nature of that binding site.

Furthermore, many orthosteric agents are glutamate derivatives or analogues of glutamate and thus lack the pharmacokinetic or CNS penetration properties desirable in a small molecule probe. A strategy that has proven more effective for achieving selectivity has been the design and use of allosteric modulators of the target. Allosteric modulators that do not activate the receptor directly but instead potentiate the activation induced by glutamate are known as positive allosteric modulators (PAMs). Conversely, molecules that bind to an allosteric site and act as noncompetitive antagonists are termed negative allosteric modulators (NAMs). In addition to the aforementioned selectivity advantages, the location of known allosteric binding sites in the transmembrane domain of the receptor has allowed for the synthesis of molecules with the balance of physiochemical properties required for penetration of the CNS.[4−6]

The study of mGlu₅ and its relation to disease has been aided tremendously by the identification and characterization of two related tool compounds that function as noncompetitive antagonists of that receptor. These molecules are the simple 1,2-diarylalkynes 2-methyl-6-(phenylethynyl) pyridine (MPEP)[7] and 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP)[8] (Figure 1). These important tool compounds have exhibited efficacy in numerous preclinical models of disease, including pain,[9] anxiety,[10−14] gastresophageal reflux disease (GERD),[15,16] and fragile X syndrome (FXS).[17,18] In addition, substantial work with these compounds using numerous animal models has furthered the understanding of the link between mGlu₅

Figure 1. mGlu$_5$ NAMs MPEP, MTEP, and fenobam. General chemical series of clinical compounds from Addex and Novartis.

and drug addiction. These compounds have demonstrated an ability to attenuate various cocaine seeking behaviors in mice,[19,20] rats,[21−26] and squirrel monkeys.[27,28] Further work established their efficacy in animal models with other drugs of abuse, including nicotine,[26,29] morphine,[30] methamphetamine,[31] and alcohol.[32−36] Finally, both MPEP and MTEP were recently found to have an antidyskinetic effect in cynomolgus monkeys treated with 4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a compound that causes rapid onset of Parkinsonism.[37] Such results indicate that antagonism of mGlu$_5$ might constitute an effective therapy for Parkinson's disease levodopa-induced dyskinesia (PD-LID), which is a complication that arises following dopamine-replacement therapy. The body of work surrounding the preclinical in vivo characterization of MPEP and MTEP is substantial and bolsters the promise of small molecule antagonists of mGlu$_5$ as therapeutics. As such, research directed toward the discovery of novel mGlu$_5$ NAMs suitable for evaluation in the clinic has been abundant.[38−40]

Further indications that a noncompetitive antagonist of mGlu$_5$ may translate into an effective therapeutic have been noted in recent years through multiple disclosures from the clinic. Addex Pharmaceuticals has reported positive data from phase II clinical studies with the mGlu$_5$ NAM ADX10059 (general chemical series[41] shown in Figure 1) in both GERD[42] and acute migraine.[43,44] FRAXA Research Foundation and Neuropharm have been exploring the potential of fenobam, a compound discovered and evaluated as an anxiolytic in the 1970s,[45] for treating FXS. In fact, Neuropharm received Orphan Drug Designation for fenobam to treat FXS in 2006. The early results from these studies in patients have been disclosed and were encouraging. Using prepulse inhibition as an outcome measure, 50% of patients (4/6 males and 2/6 females) responded according to the predefined criteria of efficacy.[46] More recent reports from Novartis with their mGlu$_5$ antagonist AFQ056 (general chemical series[47] shown in Figure 1) detailed their efforts directed toward identification of the first approved treatment for PD-LID.[48] The link between mGlu$_5$ antagonism and PD-LID was further bolstered by a recent communication from Addex describing the efficacy of both ADX10059 as well as their second generation mGlu$_5$ antagonist ADX48621 (general chemical series[41] shown in Figure 1) in a nonhuman primate model of PD-LID.[49,50] While clinical evaluation of ADX48621 continues, further development of ADX10059 was halted in late 2009 due to concerns over elevated alanine transaminase (ALT) levels in phase IIb studies in GERD patients.[51] Novartis also recently released information from a

small trial with AFQ056 in adult FXS patients. Although the trial was insufficient in length to measure effects on basic intelligence and details surrounding the trial have yet to be published, noted improvements in certain aberrant behaviors were reported.[52] AstraZeneca is evaluating two different mGlu$_5$ NAMs, AZD2066 and AZD2516, in multiple clinical studies in a variety of patients, including those who suffer from neuropathic pain and GERD.[53] Phase II studies with Roche's mGlu$_5$ NAM RG7090 in FXS and treatment resistant depression are also ongoing.[54] Seaside Therapeutics recently completed investigational new drug enabling studies with their mGlu$_5$ NAM STX107, which was in-licensed from Merck. Enrollment of a phase II study of STX107 in FXS patients was slated for 2010.[55] Details related to the chemical structures of the Seaside, Roche, and AstraZeneca compounds are not currently in the public domain.

With so much preclinical and now clinical support for noncompetitive antagonism of mGlu$_5$ as a therapeutic approach, activity in this area remains plentiful. Since the advanced compounds where chemical structures are known contain an alkyne functional group, most current efforts are focused on alternative chemotypes. New advancements in this field occur regularly, and several recent reviews highlighting progress in the discovery efforts centered on mGlu$_5$ antagonists have been published.[38−40] As such, this Review will focus on publications of nonalkyne containing series from the primary and patent literature that have occurred during the years 2009 through 2010. In deciding what information to highlight from lengthy patent applications, particular effort was made to include data for those compounds for which in vivo data, either pharmacokinetic or behavioral, was disclosed.

■ ASTRAZENECA

AstraZeneca published several separate patent applications on the same day (April 30, 2009), disclosing similar 1,2,4-triazole antagonists of mGlu$_5$ (Table 1).[56−58] One application highlighted compounds that possessed a chiral ether linkage between the 5-aryl-1,2,4-triazole and a second heterocyclic ring (**1−3**).[56] Compounds were characterized in a functional assay that measured their ability to block calcium mobilization in the presence of an agonist in cells expressing human mGlu$_5$. Further information was provided describing the brain to plasma ratio in rats following administration of the compound. The highlighted chiral ether linked compounds were quite potent; however, brain

Table 1. mGlu5 Potency and Rat Brain Penetration SAR in 1,2,4-Triazole Series

entry	series	R^1	X	Y	R^2	R^3	mGlu5 IC50 (nM)	rat B/P ratio
1	I	Cl	CHMe (R)	O	Me	A (Z = CH)	8	0.03
2	III	Cl	CHMe (R)	O	Me	A (Z = CH)	6	0.01
3	III	Cl	CHMe (R)	O	Me	A (Z = N)	5	0.075
4	II	Cl	C=O	NMe	Me	B	37	0.26
5	II	Cl	C=O	NMe	Me	C (Z = N; R^4 = H)	62	0.19
6	II	Cl	CH2	NMe	Et	C (Z = N; R^4 = H)	13	<0.01
7	II	Me	CH2	NEt	Me	C (Z = N; R^4 = H)	45	0.01
8	II	Cl	CH2	NEt	Me	C (Z = CH; R^4 = Me)	65	<0.01
9	II	Me	CH2	NEt	Me	C (Z = CH; R^4 = Me)	112	0.22
10	II	Cl	CH2	NMe	Me	D	20	0.16
11	I	Me	CH2	NEt	Me	C (Z = CH; R^4 = Me)	75	<0.01

Scheme 1[a]

[a] (i) NaH, DMF, (EtO2C)2, 0 to 80 °C, 67%; (ii) NH2OH·HCl, MeOH, 80 °C, 71%; (iii) LiAlH4, THF, 75%; (iv) NEt3, MsCl, CH2Cl2; (v) NaH, DMF, 79%; (vi) pyridine, −15 to 125 °C, 20%.

penetration was poor. Another application presented molecules with an amide linkage between the two heteroaryl rings (**4**, **5**).[57] These molecules were less potent; however, brain penetration was improved. Significantly more data was presented in the third application, which focused on alkyl amine linkages (**6**−**11**).[58] Brain penetration remained generally poor with these compounds; however, it could be improved somewhat as evidenced by N-methylpyridone **9**. The improvement may have been due to

the removal of the hydrogen bond donor in the eastern aromatic ring. Similar brain penetration was observed with a more potent 3-chlorophenyl analogue **10** in the context of an eastern pyrimidine ring, which also lacked a hydrogen bond donor. Also of note is the negative effect on brain penetration observed with the oxadiazole **11** compared to isoxazole **9**. The synthetic route for isoxazole **10** (Scheme 1) is representative of the series (yields shown where provided).[58,59] The route began with

3-chloroacetophenone **12**, which was reacted with sodium hydride and subsequently diethyl oxalate to afford dioxobutanoate **13**. Conversion to isoxazole **14** was accomplished through treatment with hydroxylamine hydrochloride. Reduction of the ester functionality was performed with lithium aluminum hydride to give alcohol **15**, which was subsequently converted to mesylate **16** using standard conditions. Reaction with the sodium anion of aminotriazole **17** gave the final compound **10**. The intermediate **17** was prepared in low yield via a single step through the reaction of acid chloride **18** with aminoguanidine **19**. Such a route is readily amenable to rapid variation of the eastern aromatic ring portion of the chemotype.

An additional six applications were filed on the aforementioned date and described a concept based on the incorporation of a conformational restraint into the previously described alkyl amine linked analogues (Figure 2).[60−65] The concept involved a carbon−carbon bond formation between the *N*-alkyl group at the 3-position of the 1,2,4-triazole and the methylene linker on the isoxazole, thus generating a cyclic tertiary amine. As before, potency and rat brain penetration data was disclosed for selected compounds in each application. The majority of the compounds for which such data was presented contained an isoxazole ring bound to the cyclic amine (Table 2). In the context of a pyrrolidine constraint with an *R*-configuration at the lone stereocenter, potent analogues were seen with carboxamide **20**[62] and aminopyridine **21**.[63] Both compounds also demonstrated low rat brain to plasma ratios; however, analogous to the prior series, brain penetration could be improved by removal of

the hydrogen bond donors on the eastern ring as evidenced by dimethylaminopyridine **22**.[63] Although, the dimethylation of **21** improved the brain to plasma ratio by over 3-fold, it also resulted in more than a 10-fold decrease in potency. One application focused on thiophene replacements for the western phenyl ring of the template (**23−25**).[64] Also contained in this application were some 2-azabicyclo[3.1.0] derivatives such as **24**. Such a modification to the pyrrolidine core appears to have little effect on potency while demonstrating some improvement in brain penetration (compare **24** to **23**). Again, the compound with the highest brain to plasma ratio (**25**) lacked a hydrogen bond donor. The remaining application provided additional 2-azabicyclo-[3.1.0] examples (**26**, **27**) as well as 3-azabicyclo[3.1.0] analogues such as **28**.[65] Potency remains similar across these examples, but brain to plasma ratios were not reported for any of the 3-azabicyclo[3.1.0] derivatives. Of note is the fact that 5-chlorothiophene **24** demonstrated higher brain to plasma ratio than its 3-chlorophenyl direct comparator **26** without compromising potency. Although specific yields are not reported for most steps, the synthesis of **22** (Scheme 2) is representative for these analogues.[63] The sequence began with the chiral pyrrolidine-2-carbaldehyde **29** which was subjected to a one-pot, three-step procedure[66] to afford isoxazole **30**. Removal of the *t*-butyl carbamate protecting group was accomplished upon treatment with trifluoroacetic acid, and the resultant amine was reacted with methyl isothiocyanate to provide thiourea **31**. Treatment with sodium *tert*-butoxide and methyl iodide gave methylated product **32**, which was subsequently reacted with hydrazide **33** in a microwave assisted process to provide final compound **22** in low yield.

Nearly a year after the simultaneous disclosure of these series, another application describing a series of related sulfide bridged analogues was published (Table 3).[67] The selected compounds within this application where mGlu$_5$ functional activity and rat brain to plasma ratios were reported were closely related chiral analogues having a methyl group (*R* configuration) appended to the carbon bridging the western heteroaryl ring to the sulfur


Figure 2. Constrained analogue concept (shown with isoxazole).

Table 2. mGlu$_5$ Potency and Rat Brain Penetration SAR in Constrained Cyclic Amine 1,2,4-Triazole Analogues

entry	series	R^1	R^2	mGlu$_5$ IC$_{50}$ (nM)	rat B/P ratio
20	I	3-chlorophenyl	A (Z = CH; R^3 = CO$_2$NH$_2$)	11	<0.01
21	I	3-chlorophenyl	A (Z = N; R^3 = NH$_2$)	<3	0.085
22	I	3-chlorophenyl	A (Z = N; R^3 = NMe$_2$)	39	0.285
23	I	5-chlorothiophen-3-yl	B (Z = N; R^3 = H)	39	<0.01
24	II	5-chlorothiophen-3-yl	B (Z = N; R^3 = H)	34	0.06
25	I	5-chlorothiophen-3-yl	B (Z = N; R^3 = Me)	61	0.16
26	II	3-chlorophenyl	B (Z = N; R^3 = H)	32	<0.01
27	II	3-chlorophenyl	B (Z = CH; R^3 = Me)	39	<0.01
28	III	3-chlorophenyl	B (Z = N; R^3 = H)	46	not reported

Scheme 2[a]

[a] (i) NaOH, $NH_2OH \cdot HCl$, $^tBuOH/H_2O$ (1:1), then $TsN(Cl)Na \cdot H_2O$, then $CuSO_4 \cdot 5H_2O$, $NaHCO_3$, 1-chloro-3-ethynylbenzene; (ii) F_3CCO_2H, CH_2Cl_2; (iii) $MeN{=}C{=}S$, CH_2Cl_2; (iv) NaO^tBu, THF, MeI; (v) ^iPrOH, pyridine, microwave, 150 °C, 2 h, 6%.

Table 3. mGlu$_5$ Potency and Rat Brain Penetration SAR in Sulfide Bridged Analogues

entry	series	A	R^1	mGlu$_5$ IC$_{50}$ (nM)	rat B/P ratio
34	I	CH	H	19	<0.01
35	I	CH	Me	87	0.10
36	I	N	H	18	<0.01
37	II	CH	H	24	0.09
38	II	CH	Me	30	0.16
39	II	N	H	41	0.04
40	III	CH	H	146	<0.01
41	III	CH	Me	380	0.02
42	III	N	H	19	0.26

Scheme 3[a]

[a] (i) NEt_3, MeMgBr, PhMe, THF, 0 °C, 46%; (ii) (R)-1-methyl-3,3-diphenylhexahydro-pyrrolo[1,2-c][1,3,2]oxazaborole, $BH_3 \cdot SMe_2$, PhMe, THF, 0 °C, 84%; (iii) NEt_3, MsCl, CH_2Cl_2; (iv) DIEA, DMSO, 90 °C, 60%; (v) $MeN{=}C{=}S$, H_2O, NaOH, 50 °C.

atom. In cases where the eastern ring was a pyridone, the activities of the tetrazole and oxadiazole analogues were similar (compare **34** to **37** and **35** to **38**); however, the corresponding

isoxazoles **40** and **41** were noticeably less potent. Interestingly, modification of the eastern ring to a pyridazinone restores the loss in potency (compare **42** to **36** and **39**). Most of these

Figure 3. 1,2,4-oxadiazole hit and SAR plan.

Table 4. mGlu$_5$ Affinity and Potency in the 1,2,4-Triazole and Tetrazole Series

Series I

Series II

| entry	series	R^1	X	R^2	mGlu$_5$ IC$_{50}$ (nM)	mGlu$_5$ K_i (nM)	SILE	LELP
49	I	3-Cl	CH$_2$CH$_2$	cyclobutyl	1170	204	3.91	3.80
50	I	3-Me	CH$_2$CH$_2$	cyclobutyl	490	126	4.26	3.02
51	I	3-OMe	CH$_2$CH$_2$	cyclobutyl	501	182	3.93	3.09
52	I	3-Me	CH$_2$	-CH$_2$OMe	30 200	186	4.15	1.77
53	I	3-Cl	CH$_2$	5-methylthiophen-2-yl	6610	123	3.86	5.05
54	I	3-Cl	S	5-methylthiophen-2-yl	759	83	3.79	5.70
55	II	3-Cl	CH$_2$CH$_2$	cyclobutyl	338	78	3.96	3.42
56	II	3-Me	CH$_2$CH$_2$	cyclobutyl	224	72	4.17	2.87
57	II	3-Cl	CH$_2$CH$_2$	5-bromofuran-2-yl	213	48	3.78	4.31
58	II	3-Cl	CH$_2$	5-methylthiophen-2-yl	251	89	3.78	4.72

analogues demonstrated very low brain to plasma ratios; however, as was seen previously, removal of the hydrogen bond donor improved brain penetration in certain cases (compare **35** to **34** and **38** to **37**). The synthetic route for isoxazole **42** (Scheme 3) is representative of the series. The synthetic sequence began with ester **43**, and reaction with methyl Grignard afforded the methyl ketone **44**. An enantioselective borane reduction using a chiral oxazaborolidine catalyst[68] was used to provide the chiral secondary alcohol **45**. Mesylate **46** was prepared using standard methods and reacted with thione **47** under basic conditions to afford final compound **42**. Thione **47** was prepared from the reaction of carbohydrazide **48** with methyl isothiocyanate.

■ GEDEON RICHTER

Work from Gedeon Richter recently described a hit to lead effort in 1,2,4-oxadiazole and tetrazole series that were structurally related to the AstraZeneca compounds outlined above.[69] High throughput screening (HTS) of their internal compound collection led to the identification of oxadiazole hit **49** as an mGlu$_5$ NAM with modest potency (Figure 3). Two different in vitro assays were used to characterize compounds. The first assay (mGlu$_5$ K_i) was a cell-based binding assay that measured affinity of the compound for the MPEP binding site using the radioligand [^{3}H]-2-((3-methoxyphenyl)ethynyl)-6-methylpyridine

(M-MPEP), a derivative of MPEP.[70] The second assay was a functional cell-based assay that measured the ability of the compound to block calcium mobilization in the presence of the orthosteric agonist (S)-3,5-dihydroxyphenylglycine. As another means of assessing the quality of compounds generated in the hit to lead process, both size independent ligand efficiency (SILE)[71] and lipophilic ligand efficiency metrics (LELP)[72] were monitored. LELP was introduced by this group as a measure of the price of ligand efficiency paid in logP. As such, higher LELP values are indicative of less druglike compounds. Evaluation of this scaffold was conducted in three separate areas of the chemotype: phenyl ring substituent(s), cyclic amine, and the amide.

Parallel synthesis was used to prepare over 650 oxadiazole analogues and over 600 tetrazole analogues that met criteria (>85% purity by LC-MS) for testing. The 2-piperidinyl, 2-pyrrolidinyl, and 4-thiazolidinyl derivatives were found most active, while 3-piperidinyl analogues were less potent. Selected compounds from these efforts are depicted here (Table 4). In the oxadiazole series, functional activity can be improved by modification of the aryl substituent as evidenced by the enhanced potency of 3-methylphenyl analogue **50** and 3-methoxyphenyl analogue **51** relative to hit compound **49**. The 2-pyrrolidine derivatives **52** and **53** were both similar in binding affinity to the 2-piperidine compounds; however, these compounds were significantly weaker in the functional assay. 4-Thiazolidine analogue

Scheme 4[a]

[a] (i) MeN(OMe)H·HCl, DIEA, DMAP, DCC; (ii) LiAlH$_4$, THF, 0 °C, 85% (2 steps); (iii) TsNHNH$_2$, EtOH, 90%; (iv) NaNO$_2$, HCl, H$_2$O, 0 °C; (v) NaOH, aq. EtOH; (vi) HCl, EtOAc, 80−90%; (vii) R^{2}CO$_2$H, EDC, NEt$_3$, CH$_2$Cl$_2$.


**Figure 4.** Carbamoyloxime HTS hit and preferred *E*-isomer.

54 does not exhibit a similar discrepancy between the two assays. The tetrazole compounds demonstrated enhanced potency and binding affinity relative to their oxadiazole counterparts (compare **55** to **49** and **56** to **50**). While all of the oxadiazole compounds were prepared and tested as racemates, tetrazole **55** was prepared as its individual pure enantiomers. Testing revealed that (*R*)-**55** (mGlu$_5$ K_i = 58 nM) displayed enhanced binding affinity relative to (*S*)-**55** (mGlu$_5$ K_i = 741 nM). The authors point out that this trend of preference for the (*R*)-enantiomer held up across multiple analogues. Interestingly, the 2-piperidine to 2-pyrrolidine modification does not result in the same dramatic discrepancy between the functional potency and binding affinity seen with the oxadiazoles (compare **58** to **53**). Analysis of their efficiency metrics led the authors to conclude that **56** represented an improved lead relative to the original hit **49**. The synthetic route employed to access tetrazole analogues such as these is shown here (Scheme 4) in the context of 2-piperidyl amides. The route began by conversion of Boc-protected piperidine-2-carboxylic acid **59** into its corresponding Weinreb's amide. Subsequent treatment with lithium aluminum hydride afforded aldehyde **60**, which was reacted with tosylhydrazide to give hydrazone **61**. Commercially available anilines **62** were converted into their corresponding diazonium salts **63** and then reacted with hydrazone **61** to provide the tetrazoles **64**. Deprotection under acidic conditions gave the free amines, which were coupled with various commercially available carboxylic acids in a parallel synthesis paradigm to yield the final products **55−57**. The incorporation of the substituted phenyl rings at a late stage and the acid monomers in the final step makes the route particularly amenable to the parallel synthesis approach employed in this endeavor.

Another series of mGlu$_5$ NAMs emerged from the HTS of the Gedeon Richter compound collection and was also described

Table 5. mGlu$_5$ Affinity and Potency in the Carbamoyloxime Series

entry	R	mGlu$_5$ IC$_{50}$ (nM)	mGlu$_5$ K_i (nM)
67	1-imidazolyl	117	11
68	2-thiophenyl	109	9.1
69	3-thiophenyl	477	14
70	4-morpholinyl		>1000
71	2-pyridyl	65	40
72	3-pyridyl	15	3
73	phenyl	151	16
74	3-fluorophenyl	127	40

recently.[73] The carbamoyloxime hit **65** demonstrated an affinity for the known MPEP binding site and behaved as a noncompetitive antagonist in the functional cell-based assay (Figure 4). Following resynthesis of **65** and separation of the *E* and *Z* isomers, it was established that the *E* isomer **66** was the more active compound. An SAR plan was implemented that centered on four separate portions of the template, which were identification of replacements for the imidazole ring, potential alternatives to the cyclohexane ring, optimization of the linker between the cyclohexane ring and aniline, and substitution of the aniline ring. Tolerance for these modifications was limited with the linker and cycloalkyl ring, and most active compounds maintained the carbamoyl oxime linked to the cyclohexane. Substitution of the aniline ring with small substituents such as chloro at the *meta*-position improved affinity and enhanced activity. The majority of SAR was developed through exploring potential replacements for the imidazole ring, and selected examples are described here (Table 5). Introduction of the 3-chloro substituent onto the aniline in the context of the imidazole ring provided **67**, which demonstrated enhanced activity relative to **66**. Compound **67** was separated into its individual enantiomers by preparative HPLC, and it was determined that the activity of **67** resulted primarily from a single enantiomer ((+)-**67** mGlu$_5$ K_i = 8.8 nM; (−)-**67** mGlu$_5$ K_i > 1000 nM). Compound **67** was examined in the Vogel punished drinking test[74] in rats and demonstrated

Scheme 5[a]

[a] (i) NH$_2$OH·HCl, NaOAc, MeOH, H$_2$O, 45 °C, then separation of E and Z isomers, 50−80%; (ii) CH$_2$Cl$_2$, 40−70%.

Scheme 6[a]

[a] (i) EtOH, μw, 130 °C, 1 h; (ii) NaBH$_4$; (iii) R^{4}NCO, μw, 80 °C, 20 min or R^{4}NH$_2$, CDI, μw, 120 °C, 20 min.

significant efficacy at doses as low as 5 mg/kg using intraperitoneal (IP) dosing. Several replacements were tolerated in place of the imidazole ring and provided analogues with similar activity to **67**. Examples include 2-thiophenyl analogue **68**, phenyl analogue **73**, and 3-fluorophenyl analogue **74**. On the other hand, the 3-thiophenyl analogue **69** had reduced activity relative to **67** while the saturated 4-morpholinyl analogue **70** had no demonstrated affinity in the binding assay. Enhanced activity was observed with 2-pyridyl analogue **71** and 3-pyridyl analogue **72**. In fact, **72** was the most potent compound in the functional assay disclosed in this paper. Several active analogues were also tested for their ability to functionally inhibit mGlu$_1$ and mGlu$_2$ and demonstrated good selectivity for mGlu$_5$. The synthesis of **67** is representative of the series and shown here (Scheme 5). Readily prepared ketone **75** was reacted with hydroxylamine to generate the oxime. The E and Z isomers were separated by either crystallization or chromatography to afford the pure E isomer **76**. Treatment with isocyanate **77** provided the final compound **67**.

■ GLAXOSMITHKLINE

A novel thiazolotriazole mGlu5 NAM chemotype was discovered through HTS of the GlaxoSmithKline compound collection.[75] With relatively low molecular weight, high polarity, ligand efficiency, and selectivity over other mGlus, the chemotype was deemed worth further exploration. A synthetic route was employed (Scheme 6) that allowed for variation of four distinct portions of the scaffold. Substituted 1,2,4-triazolethiones **78** were reacted with haloketones **79** to provide 5-carbonyl substituted thiazolotriazoles **80**. Reduction of the carbonyl group was accomplished upon treatment with sodium borohydride to afford alcohols **81**. Conversion to the carbamate final compounds **82−91** was accomplished by reaction either with the appropriate isocyanates or with carbonyl diimidazole and the appropriate primary amines. SAR developed within this

Table 6. mGlu$_5$ Potency and Protein Binding in the Thiazolotriazole Series

entry	R^1	R^2	R^3	R^4	mGlu$_5$ IC$_{50}$ (nM)	f_{ub}	pIC$_{50}$ eff
82	H	H	H	phenyl	>30 000		
83	H	Me	H	phenyl	>30 000		
84	H	H	Me	phenyl	10 000		
85	H	Me	Me	phenyl	63	6.8	6.0
86	H	Me	Me	cyclohexyl	3200		
87	H	Me	Me	3-chlorophenyl	40	0.9	5.4
88	H	Me	Me	3-fluorophenyl	50	1.7	5.5
89	H	Me	Me	3-pyridyl	316	28	5.9
90	cyclopropyl	Me	Me	phenyl	13		
91	thiophen-2-yl	Me	Me	phenyl	7.9	<0.1	<5.0

template using a cell-based calcium mobilization assay revealed that mGlu$_5$ activity was sensitive to small structural modifications (Table 6). For instance, while neither the 6-methyl group on the thiazole (**83**) nor the methyl group on the sp^3 carbon bridging the heterocycle and carbamate (**84**) provides much improvement relative to unsubstituted analogue **82**, the combination of both substituents provided potent analogue **85**. Hypothesizing that free brain concentration would be critical to achieving occupancy in vivo, the fraction unbound (f_{ub}) in rat brain homogenates was monitored for key compounds.[76] Researchers sought to balance functional potency with free brain concentration by maximizing a parameter termed pIC$_{50}$eff (pIC$_{50}$ + log$_{10}$[f_{ub}]). While saturation of the aniline ring in the form of cyclohexyl analogue **86** resulted in a loss of potency, substitution at the meta-position of the aniline ring with either chloro (**87**) or fluoro (**88**) improved potency slightly. Unfortunately the fraction unbound was considerably reduced with **87** and **88** relative to **85**, resulting in a lower pIC$_{50}$eff value. Conversely, pyridyl analogue **89**, while less potent than **85**, had a similar pIC$_{50}$eff value due to its larger fraction unbound. Substitution at the 2-position of the thiazolotriazole with cyclopropyl (**90**) or aryl groups such as thiophene (**91**) also improved potency. Fraction unbound with **91** was the lowest reported, making the compound less interesting for further studies. The noncompetitive nature of **85** was verified through in vitro studies, and it was also shown to bind to the known MPEP binding site using [^{3}H]-MPEP. Separation of **85** into its respective enantiomers by HPLC revealed a

418

dx.doi.org/10.1021/cn2000266 |ACS Chem. Neurosci. 2011, 2, 411–432

pronounced preference for a single enantiomer ((R)-**85** mGlu$_5$ IC$_{50}$ = 40 nM; (S)-**85** mGlu$_5$ IC$_{50}$ > 10,000 nM). Evaluation of (R)-**85** in a rat pharmacokinetic study demonstrated that the compound was both bioavailable and CNS penetrant (F = 28%; AUC brain:blood = 2.0). Finally, evaluation of (R)-**85** in the mouse marble burying model of anxiety established its efficacy at a dose as low as 5 mg/kg when dosed orally.[77]

ELI LILLY

A relatively narrow patent application from Eli Lilly recently described a series of isothiazole mGlu$_5$ NAMs.[78] Variation in this template focused on either hydrogen or small alkyl substituents on the cyclopropyl ring (R^1) and indazole nitrogen (R^3) (Figure 5). Claimed substituents at the 6-position of the pyridine (R^2) were broader, but exemplified compounds were generally small alkyl, cycloalkyl, alkylamino, and alkoxy substituents. Synthesis of a key exemplar compound **100** is outlined here (Scheme 7). The route was initiated with a two step kilogram scale synthesis of aminoisothiazole **93** from thioamide **92**. Reaction of **93** with acid chloride **94** provided amide **95**. Treatment of **95** with bromine and aqueous sodium hydroxide induced a deacylation/bromination reaction to afford **96**. The Suzuki coupling of **96** with the custom prepared boron reagent **97** gave intermediate **98**, which was reacted with arylstannane **99** in a Stille coupling to afford the final compound **100** (yield not provided). Compounds exemplified in this patent were tested in a functional calcium mobilization assay and found to have IC$_{50}$ values less than 75 nM. Analogue **100** was determined to have an IC$_{50}$ equal to 9.5 nM. The hydrochloride salt of **100**

was examined in a stress-induced hyperthermia (SIH) rat model, which is a well-known model of anxiety.[79] Rats were dosed orally at 0.3, 1.0, 3.0, and 10 mg/kg and immediately placed in their home cage in a dark room. After the 60 min pretreatment, the animals were individually relocated to a brightly lit room and the first core body temperature (T1) was determined. The second core body temperature reading (T2) was made 10 min later. The difference between T2 and T1 constituted the SIH response. Compound **100** produced a 35% reduction in the SIH response relative to vehicle at a dose of 3.0 mg/kg.

LUNDBECK

A patent application from Lundbeck was recently published describing a series of adamantyl diamides.[80] The application contains over 250 exemplified compounds from this general series. Preparation of symmetrical diamides was readily accomplished through coupling of adamantine-1,3-diamine **101** with suitable carboxylic acids or acid chlorides (Scheme 8). For example, a standard coupling reaction with acid **102** afforded diamide **103**, and reaction with acid chloride **104** provided diamide **105**. In the case of unsymmetrical diamides, several

Scheme 8[a]

[a] (i) DIEA, EDC, CH$_2$Cl$_2$, 80%; (ii) DIEA, CH$_2$Cl$_2$, 50%.

**Figure 5.** Isothiazole mGlu$_5$ NAMs.

Scheme 7[a]

[a] (i) AcCl, pyridine; (ii) Br$_2$, AcOH, 40 °C, 65% (2 steps); (iii) NEt$_3$, CH$_2$Cl$_2$, 82%; (iv) aq. NaOH, Br$_2$, dioxane, 5−10 °C, 85%; (v) 2 N aq. Na$_2$CO$_3$, DME, PdCl$_2$(PPh$_3$)$_2$, 83 °C, 51%; (vi) PdCl$_2$(PPh$_3$)$_2$, THF, reflux.

Scheme 9[a]

[a] (i) DIEA, BOP, CH$_2$Cl$_2$, 20%; (ii) DIEA, CH$_2$Cl$_2$.

Scheme 10[a]

[a] (i) HNO$_3$, H$_2$SO$_4$, CH$_2$Cl$_2$, 74%; (ii) conc HCl, 95 °C; (iii) MeOH, SOCl$_2$, 60 °C, 72% (2 steps); (iv) NEt$_3$, CH$_2$Cl$_2$, 97%; (v) LiOH, H$_2$O, THF; (vi) (PhO)$_2$P(O)N$_3$, NEt$_3$, PhMe, 90 °C, 86% (2 steps); (vii) pyBOP, NEt$_3$, CH$_2$Cl$_2$, 74%.

Table 7. Adamantyl Diamide Efficacy in Behavioral Assays

|	statistically significant active dose(s) (mg/kg)	
entry	mouse marble burying (SC dosing)	rat conflict test (PO dosing)
103	3, 10, 30	50
105	30	20
109	10, 30	30
116	10, 30	10, 20
117	10, 30	10, 30
118	3, 10, 30	20

different synthetic routes were employed. In an example of one method, adamantine-1,3-diamine **106** was first converted to amide **107** in low yield and subsequently reacted with acid chloride **108** to afford diamide **109** (yield not provided) (Scheme 9). A longer, more scalable route with higher yields was exemplified by the synthesis of analogue **116** (Scheme 10). The route began with 1-adamantanecarboxylic acid **110**, which was transformed via a Ritter reaction to acetamide **111**. Cleavage of the acetamide with concentrated hydrochloric acid was followed by conversion of the intermediate to methyl ester **112**. Reaction with acid chloride **104** afforded amide **113**. Hydrolysis of the methyl ester followed by a Curtius rearrangement gave amine **114**, which was then coupled

with carboxylic acid **115** to yield diamide **116**. Related analogues **117** and **118** were also prepared via the same route.

Although, compounds in the application were characterized in both a radioligand binding assay using [^{3}H]-3-methoxy-5-(pyridin-2-ylethynyl)pyridine (mPEPy),[81] a close structural analogue of MPEP, as well as a calcium mobilization assay in HEK293 cells that expressed rat mGlu$_5$, data provided for specific compounds was limited. Binding affinity values were reported for analogues **103** (mGlu$_5$ K_i = 6.7 nM) and **105** (mGlu$_5$ K_i = 40 nM). While the lack of specific in vitro data makes determination of SAR difficult, of particular interest was the reported in vivo activity of selected compounds (Table 7). Compounds were evaluated for their anxiolytic effects in a mouse marble burying model[77] as well as a modified Geller—Seifter conflict test in rats.[82] While the mouse studies were conducted with subcutaneous dosing, the rat studies used oral dosing. Without functional activity and exposure data, it is not possible to draw correlations to the efficacy data; however, several compounds demonstrated efficacy in the 10—30 mg/kg dose range.

■ MERZ

A recent patent application from Merz contained over 300 exemplified compounds from a 6-halopyrazolo[1,5-a]pyrimidine series.[83] Although biological data was not provided for the

Table 8. Functional mGlu₅ Activity and Binding Affinity in the Pyrazolopyrimidine Series


entry	series	X	R	chirality	CHO-K1 mGlu$_5$ IC$_{50}$ (nM)	astrocytes mGlu$_5$ IC$_{50}$ (nM)	mGlu$_5$ K_i (nM)
119	I	Cl			166	82	247
120	I	Br			189	64	281
121	II	Cl	Me	(±)	327	87	275
122	II	Br	Me	(±)	223	50	219
(R)-**122**	II	Br	Me	R	118	34	74
123	II	Cl	Cl	(±)	91	22	42
124	II	Br	Cl	(±)	84	23	45
(R)-**124**	II	Br	Cl	R	25	7.8	not reported
125	II	Cl	Br	(±)	34	17	73
126	II	Br	Br	(±)	75	15	55

Scheme 11[a]

[a] (i) MeOH, SOCl₂, reflux; (ii) H₂, Pd/C, THF, AcOH, 88% (2 steps); (iii) conc HCl, EtOH, BrCH(CHO)₂, 18%; (iv) aq. H₂SO₄, heat; (v) EDC, HOBt, DMF, 50 °C; (vi) H₂NCH₂CH₂NH₂, aq. HCl, reflux, 70%; (vii) Et₃N·HCO₂H, MeCN, 99%.

majority of these compounds, selected compounds were characterized in two cell-based functional assays as well as a radioligand binding assay with [³H]-M-MPEP (Table 8). Both functional assays were calcium mobilization assays that measured the compounds' ability to potentiate the response to the orthosteric agonist L-quisqualic acid. One functional assay was run in stably transfected Chinese hamster ovary (CHO-K1) cells that express human mGlu₅, while the second was run in primary astrocytes prepared from cortices of newborn rats. In general, there was good agreement between the three assays, and the SAR trends were similar. Tetrahydrocinnoline amides **119** and **120** (Series I) do not contain a chiral center; however, the tetrahydropyrrolopyrazine amides **121**−**126** were substituted with a methyl group at the 1-position of the ring, resulting in a chiral center. Potency and binding affinity of these analogues were enhanced by the replacement of the 6-methyl substituent on the tetrahydropyrrolopyrazine ring with a chloro or bromo substituent (compare **123** and **125** to **121** as well as **124** and **126** to

122). Also of note is the improved potency observed with the pure enantiomers (R)-**122** and (R)-**124** relative to their respective racemates. The synthesis of (R)-**122** is shown here and is indicative of the general routes to the pyrazolopyrimidine analogues discussed here. The synthesis of carboxylic acid **130** began with the Fischer esterification and subsequent reduction of nitropyrazole acid **127** to provide aminopyrazole **128** (Scheme 11).[84] Treatment of **128** with concentrated hydrochloric acid in the presence of 2-bromomalonaldehyde afforded pyrazolopyrimidine **129**. Hydrolysis of the methyl ester under acidic conditions gave carboxylic acid **130**, which was coupled with amine **131** under standard conditions to provide final compound (R)-**122** (yield not provided). The synthesis of chiral amine **131** was accomplished in two steps beginning with the acid mediated reaction of ethylenediamine with furan **132** to yield pyrrolopyrazine **133**. Asymmetric transfer hydrogenation of **133** with chiral ruthenium catalyst **134** gave **131** in near quantitative yield.

Scheme 12[a]

[a] (i) ArCO$_2$H, CDI, pyridine or ArCOCl, pyridine, NEt$_3$, CH$_2$Cl$_2$, 50−75%; (ii) ArB(OH)$_2$, Pd(PPh$_3$)$_4$, 2N aq. Na$_2$CO$_3$, PhMe, 110 °C or DME/H$_2$O (3:1), 80 °C, 75−80%.

**Table 9. Functional mGlu$_5$ Activity and Binding Affinity in the Aryl Amide Series**

| entry	R^1	R^2	R^3	mGlu$_5$ IC$_{50}$ (nM)	mGlu$_5$ K$_i$ (nM)
136	Cl	H	H	1870	1730
137	CN	H	H	490	330
138	CN	H	F	22	66
141	3-pyridyl	H	F	not tested	702
142	CN	Ph	H	14	9.8
143	H	Ph	H	not tested	7000
144	CN	3-fluorophenyl	H	25	22
145	CN	4-fluorophenyl	H	4.6	134
146	CN	1-naphthyl	H	640	72
147	CN	3-pyridyl	H	>1000	2040

■ NATIONAL INSTITUTE ON DRUG ABUSE

A group of researchers at NIDA has previously reported on a rational design strategy in an aryl amide series of mGlu$_5$ NAMs.[85,86] Further information regarding continued effort within this general chemotype and additional characterization of selected molecules has been published recently.[87] The synthesis of many of the compounds in this paper began with 6-methyl-2-aminopyridine **135** (Scheme 12). Coupling of **135** with aryl carboxylic acids or acid chlorides afforded amides **136−140**. In cases where R^1 (**139**) or R^2 (**140**) was a bromide, those analogues were further reacted with aryl boronic acids using Suzuki coupling conditions to generate additional analogues **141−147**. Compounds were characterized in a calcium mobilization assay (mGlu$_5$ IC$_{50}$) run in HEK293 cells that expressed rat mGlu$_5$ as well as a radioligand binding assay (mGlu$_5$ K$_i$) with [^{3}H]MPEP (Table 9). In general, there was good agreement between these assays; however, there were some exceptions. Prior work in this series had shown that simple exchange of a chloro substituent (**136**) for a cyano group (**137**) produced a near 4-fold improvement in potency.[85] The further introduction of a 5-fluoro substituent to provide analogue **138** further enhanced activity by over 20-fold. Replacement of the cyano group with a 3-pyridyl ring (**141**) was not well tolerated; however, introduction of a phenyl ring at the R^2 position of **137** gave biaryl analogue **142**, which was among the most potent

of analogues tested. Interestingly, the cyano group was shown to be essential as analogue **143** demonstrated dramatically reduced affinity in the radioligand binding assay. Fluorinated analogues of **142** (**144−145**) were similarly potent; however, there was a disparity between the binding affinity and functional potency observed with **145** that was not seen with **144**. Replacement of the phenyl group with a 1-naphthyl (**146**) or a 3-pyridyl (**147**) ring was not favorable. Compounds were also evaluated in mGlu subtype functional assays, and none demonstrated more than 70% inhibition of phosphatidylinositol (PI) hydrolysis at a concentration of 10 μM. Further, compounds **142** and **144** demonstrated only weak activity in off target assays measuring interactions with the dopamine, serotonin, and norepinephrine transporters.

Concurrent to their work in the aforementioned aryl amides, NIDA reported on similar efforts in several biaryl chemotypes, including 7-substituted quinolines.[88] As the biaryl quinoline template was among the most promising, work was continued in that chemotype and recently disclosed.[89] New 7-phenylquinoline analogues were prepared by the synthetic route shown here (Scheme 13). Bromination of 3-chlorobenzonitrile **148** with 1,3-dibromo-5,5-dimethylhydantoin **149** according to the literature procedure afforded aryl bromide **150**.[90] A Suzuki coupling with boronic acids **151−153** gave the biaryl products **154−156**. A second Suzuki coupling between the aryl chloride and boronate ester **158** was accomplished in the presence of phosphine ligand **157** to afford the final products **159−161**. A modified synthetic approach was used to access 7-(pyridin-3-yl)quinoline analogues (Scheme 14). The route began with either 5-bromonicotinonitrile **162** or 5-bromo-2-chloronicotinonitrile **163**. Suzuki coupling with boronate ester **158** afforded biaryls **164** and **165**. A second Suzuki coupling of **165** with phenyl boronic acid **151** using phosphine ligand **157** provided analogue **166**. The profile of quinoline analogues in both the functional and radioligand binding assays is shown here (Table 10). Unsubstituted analogue **167** was prepared and reported previously by NIDA,[87] and it was also independently prepared and discussed previously by a group at Pfizer.[91] The addition of phenyl (**159**) or 4-fluorophenyl (**161**) substituents led to compounds with similar binding affinity to **167**; however, potency in the functional assay was reduced significantly. Introduction of a 3-pyridyl (**160**) group alleviated the discrepancy between the two assays, but both affinity and potency were compromised relative to **167**. Alteration of the scaffold to introduce a pyridyl nitrogen in the internal ring was more successful, as both unsubstituted analogue **164** and phenyl substituted analogue **166** were similar in activity to **167**.

422

dx.doi.org/10.1021/cn2000266 |ACS Chem. Neurosci. 2011, 2, 411−432

Scheme 13[a]

[a] (i) H_2SO_4, F_3CCO_2H, 76%; (ii) Pd(PPh$_3$)$_4$, Na$_2$CO$_3$, DME, H$_2$O, 70 °C, 40−75%; (iii) Pd(OAc)$_2$, K$_3$PO$_4$, **157**, dioxane, H$_2$O, 105 °C, 33−42%.

Scheme 14[a]

[a] (i) PdCl$_2$(dppf), Na$_2$CO$_3$, **158**, dioxane, H$_2$O, μw, 140 °C, 65−80%; (ii) Pd(OAc)$_2$, **151**, K$_3$PO$_4$, **157**, dioxane, H$_2$O, μw, 140 °C, 30%.

**Table 10. Functional mGlu$_5$ Activity and Binding Affinity in the Quinoline Series**

entry	A	R	mGlu$_5$ IC$_{50}$ (nM)	mGlu$_5$ K_i (nM)
167	CH	H	29	110
159	CH	phenyl	1250	97
160	CH	3-pyridyl	1340	730
161	CH	4-fluorophenyl	692	64
164	N	H	68	100
165	N	Cl	3310	>10 000
166	N	phenyl	81	97

Intermediate chloropyridine **165** was also tested, and although it was weak in both assays, the compound was a clear partial antagonist in the functional assay. In this case, the concentration response curve with **165** reached only a 50% inhibition of the EC$_{80}$ glutamate response. Subtle SAR between full and partial antagonists has been previously noted within alkyne chemotypes in the literature.[92,93]

NOVARTIS

HTS based on the ability of compounds to inhibit agonist induced elevation of intracellular calcium (Ca^{2+}) was used by Novartis to identify a novel nicotinamide series of mGlu$_5$ NAMs. A recent publication described a thorough evaluation of the SAR within this chemotype.[94] Two general synthetic routes were used to access compounds within this template (Scheme 15). One route allowed for the introduction of the eastern portion of the chemotype as the final step. Acid chlorides **168** were reacted with amines to yield amides **169**. Subsequent S$_N$Ar reaction with aryl amines **170** under acidic conditions afforded the final compounds **171**−**183**. A second route used an amide coupling of the hydrolyzed esters of **185** as the final step. The esters **185** were prepared from a Buchwald coupling of aryl amines **170** with 2-chloropyridines **184**. The HTS hit and starting point for SAR development was piperidinyl amide **171** (Table 11). Evaluation of other secondary amine amides indicated that piperidinyl (**171**) and azepanyl (**173**) amides were superior to pyrrolidinyl (**172**) and azocanyl (**174**) amides, and the majority of the remaining SAR was developed in the context of piperidinyl amides. The importance of the 4-chloro substituent on the aniline moiety was illustrated with unsubstituted aniline analogue **175**. Potency could be partially restored with other 4-substituents (**176**−**178**), though not to the level seen with **171**. A 3-fold improvement in potency relative to **171** was seen with the introduction of a chloro group at the 3-position of the pyridine core (**180**). A similar 5-fold improvement was observed when comparing **181** to **179**.

Using the 5-amino-2-methylpyridine analogue **181** as a starting point, further derivatization of the piperidinyl ring was made (Table 12). Compounds were also evaluated for their solubility as well as their stability in rat and human liver microsomes. While incorporation of an ethyl group at the 3-position of the piperidinyl ring improved potency with both enantiomers (**182**), metabolic stability was reduced. Also of note was the difference in solubility observed between the two enantiomers. In the case of the 2-ethyl piperidinyl ring, there was a significant difference in potency between the two enantiomers, with a 12-fold preference for the R-configuration relative to the S-configuration (**183**). Having determined that (R)-**183** offered the optimal balance of

Scheme 15[a]

[a] (i) NEt$_3$, HNR^{1}R^2, CH$_2$Cl$_2$, 0 °C; (ii) AcOH, H$_2$O (3:7), 95 °C; (iii) Pd(OAc)$_2$, BINAP, K$_2$CO$_3$, PhMe, 70 °C; (iv) 2 N aq. NaOH, MeOH, 60 °C; (v) HATU, DIEA, DME.

Table 11. Functional mGlu$_5$ Activity in the Nicotinamide Series

| entry	n	X	A	R	mGlu$_5$ IC$_{50}$ (nM)
171	1	H	CH	Cl	310
172	0	H	CH	Cl	5400
173	2	H	CH	Cl	250
174	3	H	CH	Cl	2300
175	1	H	CH	H	~10 000
176	1	H	CH	F	2300
177	1	H	CH	Me	2300
178	1	H	CH	OMe	1800
179	1	H	N	Me	420
180	1	Cl	CH	Cl	95
181	1	Cl	N	Me	87

properties, the compound was studied in a rat pharmacokinetic study. The compound demonstrated moderate clearance (37.2 mL/min/kg) and good bioavailability (54%). Importantly, CNS penetration with (*R*)-**183** was excellent with a brain to plasma ratio around 1.3 to 1. Given such promising data, analogue (*R*)-**183** was studied in three separate rodent behavioral models of anxiety. The SIH model was evaluated in mice,[79,95] and (*R*)-**183** was efficacious at 3 and 10 mg/kg using oral dosing. Further evaluation in rats was conducted using the Vogel conflict test[74,96] and the fear-potentiated startle test (FPS).[97,98] Dose dependent efficacy was observed with oral dosing in both experiments with significance at 10 and 30 mg/kg in the Vogel test and 3, 10, and 30 mg/kg in the FPS test.

Novartis researchers continued further optimization efforts in the (*R*)-**183** series and published results from that effort recently.[99] Metabolite identification studies revealed that the piperidine moiety of (*R*)-**183** was a major site of oxidative metabolism. As such, medicinal chemistry was focused on the identification of a suitable bioisosteric replacement. Several heterocyclic alternatives were explored including oxadiazoles, triazoles, and isoxazoles and shown to lack suitable activity for further work. Fortunately a 1-alkyl-2-benzimidazolyl group was identified as a promising alternative and SAR exploration was

conducted in that area (Table 13). *n*-Propyl analogue **186**, ethyl analogue **187**, and isobutyl compound **189** were similar in activity, while the *n*-butyl analogue **188** was less active. The metabolic stability profiles of **186** and **187** were preferable to those for **188** and **189**. Installation of a chloro substituent at each of the positions on the benzimidazole ring (**190**−**193**) maintained or reduced intrinsic clearance in both rat and human liver microsomes relative to **186**, with the intrinsic clearance of **191** in rat liver microsomes representing the lone exception. The improved potency and encouraging metabolic stability of **193** led to further study of that compound. Radioligand binding assays with [^{3}H]-ABP688[100] showed that **193** demonstrated a high affinity for the known allosteric binding site (mGlu$_5$ K_i = 2.4 nM). Compound **193** was also shown to be selective against other mGlus (IC$_{50}$ > 10 μM for mGlu$_1$, mGlu$_2$, and mGlu$_7$) and ionotropic glutamate receptors. Although the intrinsic clearance in rat liver microsomes for **193** and (*R*)-**183** was nearly identical, the in vivo profile for **193** was superior. Clearance was lower (15 mL/min/kg), and bioavailability remained good (41%). Furthermore, CNS penetration remained excellent with a brain to plasma ratio around 1.7 to 1. Evaluation of **193** in the FPS model[97,98] using oral dosing demonstrated efficacy in a dose dependent manner with significant responses at both 1 and 3 mg/kg. A four-step synthesis of **193** was employed (Scheme 16). A palladium catalyzed coupling of 2,3-dichloropyridine **194** with amine **195** gave ester **196**, which was hydrolyzed to afford acid **197**. Reaction with 1,2-phenylenediamine **198** in hot polyphosphoric acid (PPA) yielded benzimidazole **199**. Alkylation with *n*-propyl iodide gave the final compound **193** in low yield following separation from its regioisomer **190**.

■ SEPRACOR

A rational design approach to new mGlu$_5$ NAMs was employed by researchers at Sepracor, and results from that effort were recently disclosed.[101] Their approach centered on novel methods for tethering two aryl groups as alternatives to traditional linkers such as alkynes, amides, and azoles. Several potential scaffolds were prepared before settling on oxazolopiperidine **200** (Figure 6). Compound **200** was a moderately potent mGlu$_5$ NAM in their functional assay, which was run in an inducible cell line expressing human mGlu$_5$. SAR exploration established the 2-pyridyl ring as optimal for the western portion of the template, and the 3-cyanophenyl ring was similarly optimal

424

dx.doi.org/10.1021/cn2000266 |*ACS Chem. Neurosci.* 2011, 2, 411–432

Table 12. mGlu$_5$ Potency, Solubility, and Intrinsic Clearance in the Nicotinamide Series

entry	R^1	R^2	mGlu$_5$ IC$_{50}$ (nM)	solubility at pH 6.8 (mg/mL)	rat Cl$_{INT}$ (μL/min/mg)	human Cl$_{INT}$ (μL/min/mg)
181	H	H	87	150	48	33
(R)-**182**	H	R-ethyl	40	95	643	322
(S)-**182**	H	S-ethyl	40	<3	687	174
(R)-**183**	R-ethyl	H	32	58	87	89
(S)-**183**	S-ethyl	H	390	56	190	216

Table 13. mGlu$_5$ Potency and Intrinsic Clearance in 2-Benzimidazolyl Analogues

entry	R^1	R^2	R^3	R^4	R^5	mGlu$_5$ IC$_{50}$ (nM)	rat Cl$_{INT}$ (μL/min/mg)	human Cl$_{INT}$ (μL/min/mg)
186	^{n}Pr	H	H	H	H	100	83	158
187	Et	H	H	H	H	110	120	118
188	^{n}Bu	H	H	H	H	360	347	279
189	^{i}Bu	H	H	H	H	110	55	826
190	^{n}Pr	Cl	H	H	H	200	74	69
191	^{n}Pr	H	Cl	H	H	>500	400	34
192	^{n}Pr	H	H	Cl	H	130	56	33
193	^{n}Pr	H	H	H	Cl	24	83	112

Scheme 16^a

^{a} (i) Pd$_2$(dba)$_3$, K$_2$CO$_3$, BINAP, PhMe, 120 °C, 16 h, 56%; (ii) 1 N aq. NaOH, MeOH, 95%; (iii) PPA, 200 °C, 16 h, 74%; (iv) NaH, ^{n}PrI, DMF, 10%.

for the eastern portion. Additional SAR was established in the interior of the scaffold in the context of these substituents (Table 14). Maintaining the oxazolopiperidine core of **200** in the context of the optimized peripheral groups gave analogue **201**, which was a potent antagonist. The isomeric oxazole **202** was less potent than **201**. The installation of a 5-fluoro group on the phenyl ring boosted potency in both instances (**203** and **204**). Imidazole **205** and thiazole **206** were weak antagonists. While imidazole **207** and triazole **208** were also potent, both were inferior to oxazole **203**. A final modification that further enhanced potency was enlargement of the saturated ring by one carbon to afford azepines **209** and **210**. Radioligand binding assays with **203** and **210** using [3H]-MPEP confirmed their interaction with the known allosteric binding site. Both

425

dx.doi.org/10.1021/cn2000266 |ACS Chem. Neurosci. 2011, 2, 411–432

mGlu$_5$ IC$_{50}$ = 1200 nM

Figure 6. Hit oxazolopiperidine **200**.

Table 14. mGlu$_5$ Potency in Tetrahydroazolopyridines and Tetrahydroazoloazepines

entry	n	X	Y	Z	R	mGlu$_5$ IC$_{50}$ (nM)
201	1	O	C	N	H	60
202	1	N	C	O	H	290
203	1	O	C	N	F	28
204	1	N	C	O	F	54
205	1	N	C	NH	F	34% at 10 μM
206	1	N	C	S	F	52% at 10 μM
207	1	C	N	N	F	153
208	1	N	N	N	F	346
209	2	O	C	N	H	65
210	2	O	C	N	F	16

Table 15. Receptor Occupancy and Exposures for 203 and 210 in Rats

| entry	mGlu$_5$ IC$_{50}$ (nM)	mGlu$_5$ K_i (nM)	% RO	plasma levels (nM)	brain levels (nM)	RO$_{50}$ (mg/kg)
203	28	17	45	2490	1290	>30
210	16	17	82	1430	1100	0.9

molecules were also examined for off target activity and were found to have quite clean profiles. With a good correlation between the binding and functional assays, both molecules were examined in occupancy studies in rats using [³H]-mPEPy (Table 15). Compounds were dosed IP, and [³H]-mPEPy was dosed by tail-vein injection 1 h later. Both compounds showed good CNS penetration; however, **210** was a superior compound, demonstrating an occupancy ED$_{50}$ of 0.9 mg/kg. Compound **210** was next taken into rat and monkey bioavailability studies (rat: Cl$_p$ = 46.5 mL/min/kg; F = 31%; $t_{1/2}$ = 0.62 h; monkey: Cl$_p$ = 16.3 mL/min/kg; F = 10%; $t_{1/2}$ = 0.67 h). The authors believe such results are less than desirable and plan to continue to work to improve the pharmacokinetics of analogues within this scaffold. The synthesis of **210** is described here (Scheme 17). Piperidinone **211** was brominated to yield bromoketone **212**. Reaction with ethyl diazoacetate in an Eistert homologation afforded azepine **213**. Hydrolysis and decarboxylation was accomplished under acidic conditions. Standard conditions were then used to access azide **214**, which was treated with lithium aluminum hydride to give the amino alcohol **215**. Amide formation through coupling with picolinic acid was followed by a Dess−Martin oxidation to provide ketone **216**. Treatment with

Burgess' reagent under microwave conditions gave oxazoloazepine **217**. Removal of the tosyl protecting group and subsequent Buchwald coupling of amine **218** with 3-bromo-5-fluorobenzonitrile provided the final product **210** in low yield.

■ VANDERBILT

The Vanderbilt Program in Drug Discovery has used a functional cell-based HTS of a collection of 160 000 compounds to identify 345 confirmed noncompetitive antagonists of mGlu$_5$. The initial report of the SAR within three distinct series that were identified through this screen was reported in early 2009[102] and has been discussed in a prior review.[38] Further efforts with different chemical scaffolds that were discovered through this HTS effort have been communicated since this initial publication. One such effort focused on a series of 6-substituted-4-anilinoquinazolines.[103] Analogues within this series were prepared through reaction of commercially available anilines and the requisite 4-chloroquinazolines using microwave-assisted organic synthesis (MAOS).[104] SAR demonstrated that 4-anilinoquinazolines were superior to the comparator 4-anilinoquinolines and 1-anilinoquinolines, and that the secondary amine was the optimal linker between the quinazoline and the phenyl ring. The majority of SAR evaluation was centered on the 6-position of the quinazoline and on substitution of the aniline ring (Table 16). Potency data for compounds was determined using a functional assay that measured the ability of compound to block the mobilization of calcium by an EC$_{80}$ concentration of glutamate in HEK293 cells expressing rat mGlu$_5$. The screening hit in this series was 6-bromoquinazoline **219**. Substitution of the aniline was critical to potency as evidenced by unsubstituted analogue **220**. Tolerance for substitution was limited although both aryl bromide **222** and methyl analogue **223** were similar in potency to the hit compound. A similar trend was noted with regard to substitution at the 6-position on the quinazoline ring, where chloro (**225** and **229**) and fluoro (**226** and **230**) analogues were also potent antagonists. In this case, a 6-nitroquinazoline **227** was also similar in potency to the hit compound. Additional SAR was conducted in context of the 6-fluoroquinazoline (**230**−**234**), and SAR was somewhat shallow. Analogues **219**, **229**, and **230** were determined to interact with the known allosteric binding site through radioligand binding studies with [³H]-mPEPy. Further, when the same three compounds were tested against other mGlus, all were inactive up to 10 μM, except for mGlu$_1$, where potency was submicromolar in each case.

A third publication from the Vanderbilt group describing the HTS follow-up recently appeared.[105] Although the publication describes three distinct chemotypes discovered in the HTS, the majority of the SAR discussion centers on an N,N'-(1,3-phenylene)diamide series. The preparation of these compounds begins with commercially available 3-nitroaniline **235** (Scheme 18). Amide formation with either 2-methoxy or 3-chlorobenzoyl chloride was accomplished under standard conditions to afford **236** and **237**, respectively. The reduction of the nitro group via Raney nickel hydrogenation gave anilines **238** and **239**. A parallel synthesis, library approach was used in reactions with acid chlorides and with the aid of resin bound scavengers to provide final compounds **240**−**255** (Table 17). The hit compound in this series was dibenzamide **240**, which was confirmed to bind at the MPEP binding site through studies with [³H]-mPEPy (mGlu$_5$ K_i = 1100 nM). Multiple examples were prepared with a methoxy group at R^1 and substituted phenyl rings at R^2.

426

dx.doi.org/10.1021/cn2000266 |ACS Chem. Neurosci. 2011, 2, 411–432

Scheme 17[a]

211 → **212** → **213** → **214** → **215** → **216** → **217** R = Ts / **218** R = H / **210** R = 3-cyano-5-fluorophenyl

[a] (i) Br$_2$, CH$_2$Cl$_2$, −5 to −2 °C, 98%; (ii) ethyl diazoacetate, BF$_3$·OEt$_2$, CH$_2$Cl$_2$, −5 to 0 °C, 72%; (iii) 3 N aq. HCl, dioxane, 100 °C, 90%; (iv) NaN$_3$, DMF, 80%; (v) LiAlH$_4$, THF, 0 °C, 52%; (vi) picolinic acid, EDC, HOBt, NEt$_3$, CH$_2$Cl$_2$, 80%; (vii) Dess−Martin periodinane, CH$_2$Cl$_2$, 92%; (viii) Burgess' reagent, THF, 150 °C, μw, 45 min, 78%; (ix) 48% aq. HBr, 100 °C, 74%; (x) 3-bromo-5-fluorobenzonitrile, Pd$_2$(dba)$_3$, XANTPHOS, KO^{t}Bu, PhMe, μw, 100 °C, 22%.

Table 16. mGlu$_5$ Potency in the Quinazoline Series

| entry	R^1	R^2	mGlu$_5$ IC$_{50}$ (nM)
219	Br	Cl	256
220	Br	H	>10 000
221	Br	F	1970
222	Br	Br	174
223	Br	Me	246
224	Br	OMe	>10 000
225	Cl	Cl	130
226	F	Cl	311
227	NO$_2$	Cl	274
228	OMe	Cl	1510
229	Cl	Br	124
230	F	Br	96
231	F	Me	1350
232	F	CF$_3$	>10 000
233	F	CN	1370
234	F	OMe	>10 000

Tolerance for substitution in these cases was limited to the 3-position (compare **241** and **242** to **240**). Other substituents at the 3-position failed to yield compounds with superior potency to hit **240** (**243**−**246**). Installation of nonbenzamide groups at R^2 led to multiple inactive compounds such as benzyl amide **247**. Choosing to hold the 3-chlorobenzamide constant led to a second library of compounds without improvement on hit **240**. Still, several moderately potent compounds were obtained with small cycloalkyl amides (**252** and **253**). Potency quickly fell off if the cycloalkyl amide was too large as noted with cyclopentyl amide **251**. Also of note were isonicotinamide **254** (EC$_{50}$ = 1870 nM; Glu$_{max}$ = 49%) and nicotinamide **255** (EC$_{50}$ = 5540 nM; Glu$_{max}$ = 56%), which acted as PAMs. Such an example is particularly interesting, as it constitutes an example of pharmacology mode switching in a nonalkyne mGlu$_5$ series.

Follow up work to the HTS screen yielded a fourth publication in 2010 focused on developing SAR around an oxadiazole hit compound **256** (Table 18).[106] The oxadiazole series was previously disclosed as mGlu$_5$ NAMs in a patent application from NPS Pharmaceuticals;[107] however, Vanderbilt continued work in this series with the goal of developing a new, useful tool compound in a series without an alkyne or amide moiety. Compounds in this series can be prepared in a single step through a condensation reaction of 2-pyridylamidoxime with substituted benzoic acids. Although most new analogues (**257**−**259**) failed to achieve improved potency relative to hit compound **256**, 3-cyano-5-fluorophenyl analogue **260** was a notable improvement and was selected for extensive evaluation as a potential tool compound. Radioligand binding studies revealed that **260** was fully competitive with [^{3}H]-mPEPy (mGlu$_5$ K_i = 17 nM), suggesting an interaction with the known allosteric binding site. Further studies with the neutral ligand 5MPEP[93] confirmed this interaction. Compound **260** also demonstrated an ability to induce rightward shifts of the glutamate concentration response curve while decreasing the maximal response to glutamate, a profile consistent with noncompetitive inhibition. Compound **260** was determined to be selective over other mGlus. Evaluation of **260** in a modified version of the Geller−Seifter conflict paradigm model[12,82] in rats revealed that the compound dose dependently increases punished responding relative to vehicle at 3 and 10 mg/kg (IP dosing) and significantly decreased unpunished responding a the 10 mg/kg dose. Compound **260** was also efficacious in the mouse marble burying model of anxiety,[77] demonstrating a significant decrease in marble burying relative to vehicle at the 10 mg/kg dose (IP dosing). The anxiolytic effects observed here with **260** were comparable to MTEP, which was run as a positive control. A particularly interesting experiment presented here examined **260** and MTEP in a PCP-induced hyperlocomotion model in rats, a model of psychotomimetic-like activity. Both compounds were dosed IP at 10 mg/kg, and while MTEP produced a robust potentiation of PCP induced hyperlocomotion, no such activity was observed with **260**.

427

dx.doi.org/10.1021/cn2000266 |ACS Chem. Neurosci. 2011, 2, 411−432

Scheme 18[a]

[a] (i) 2-Methoxybenzoyl chloride or 3-chlorobenzoyl chloride, DIEA, DMAP, DMF, 64–89%; (ii) H_2, Raney nickel, EtOH, EtOAc, 89–94%; (iii) R^2COCl, PS-DMAP, PS-DIEA, then PS-isocyanate and PS-trisamine.

Table 17. mGlu$_5$ Potency in the N,N'-(1,3-Phenylene)Diamide Series

entry	R^1	R^2	mGlu$_5$ IC$_{50}$ (nM)
240	2-OMe	3-chlorophenyl	880
241	2-OMe	2-chlorophenyl	>30 000
242	2-OMe	4-chlorophenyl	>30 000
243	2-OMe	3-fluorophenyl	6480
244	2-OMe	3-methylphenyl	1350
245	2-OMe	3-(CF$_3$)phenyl	10,600
246	2-OMe	3-cyanophenyl	1800
247	2-OMe	benzyl	>30 000
248	3-Cl	2-chlorophenyl	2620
249	3-Cl	3-chlorophenyl	>30 000
250	3-Cl	2-furyl	4510
251	3-Cl	cyclopentyl	>30 000
252	3-Cl	cyclobutyl	5270
253	3-Cl	cyclopropyl	2230
254	3-Cl	isonicotinamide	PAM
255	3-Cl	nicotinamide	PAM

Table 18. mGlu$_5$ Potency in Oxadiazole Series

entry	R^1	R^2	mGlu$_5$ IC$_{50}$ (nM)
256	OMe	OMe	62
257	H	CF$_3$	2360
258	H	Cl	240
259	H	Br	215
260	F	CN	24

Table 19. mGlu$_5$ Potency in 3-Cyano-5-fluoro-N-arylbenzamide Series

entry	R	mGlu$_5$ IC$_{50}$ (nM)
138	6-methylpyridin-2-yl	65
261	4-methylthiazol-2-yl	59
262	1-methyl-1H-pyrazol-3-yl	>10 000
263	4-cyclopropylthiazol-2-yl	900
264	phenyl	5440
265	3-chlorophenyl	45
266	3-methylphenyl	122
267	3-chloro-2-fluorophenyl	347
268	3-chloro-4-fluorophenyl	377

In addition to pursuing new mGlu$_5$ NAM scaffolds based on their HTS results, Vanderbilt has also been investigating rational design approaches. One such effort was published recently and described SAR in a series of 3-cyano-5-fluoro-N-arylbenzamides.[108] Recognizing the prevalence of 3-cyano-5-fluorophenyl rings found across known mGlu$_5$ NAM scaffolds (see **138**, **203**, **210**, and **260** for examples), chemists used a library approach to rapidly generate new amide analogues prepared from 3-cyano-5-fluorobenzoic acid according to standard methods (Table 19). Several heteroaryl amides were prepared, and most new analogues were only weak antagonists as was observed with compound **262**. The 6-methylpyridine analogue **138** was previously described by NIDA (Table 9) and demonstrated the expected potent activity. Isosteric 4-methylthiazole analogue **261** had not been previously described and was equally potent. Tolerance for substitution of the thiazole was limited as exemplified by compound **263**. Noting the weak antagonist activity observed with simple aniline analogue **264**, a series of substituted aniline analogues were

prepared. Anilines substituted with small 3-substituents (**265** and **266**) demonstrated substantially enhanced potency relative to **264**. Also of interest were the results with regioisomeric analogues **267** and **268**. Although their IC$_{50}$ values were nearly identical, like most of the potent compounds reported here, **267** was a full antagonist; however, **268** was a clear partial antagonist. In the case of partial antagonists, the complete response curve plateaus whereas full antagonists bring the curve near to zero. In this case, at a 30 μM top concentration of **268**, the amplitude of response as a percentage of maximal response

(100 μM glutamate) plateaus at 43%. Radioligand binding studies with [^{3}H]-mPEPy verified the interaction of four compounds (**138**, **261**, **265**, and **266**) with the known allosteric binding site. Following evaluation of the same four compounds in microsomal stability assays, both **261** and **265** were evaluated in rat pharmacokinetic studies using IP dosing at 10 mg/kg doses. The CNS penetration was quite good with both compounds (brain to plasma ratios = 4.1 (**261**) and 1.4 (**265**)). Furthermore, protein binding studies with each compound (rat plasma = 92.4% bound (**261**) and 93.7% bound (**265**)) indicated that ample free fraction is available to make both potentially interesting tool compounds. Current efforts are focused in that area.

■ CONCLUSION

Considering the aforementioned cases of positive clinical reports with mGlu$_5$ NAMs and the immense effort from groups across the globe directed toward the discovery and optimization of many diverse chemotypes, the likelihood of a molecule making it to market in the future would seem high. Extensive effort has identified a number of templates that contain the alkyne moiety found in earlier compounds such as MTEP and MPEP. Other than the previously discovered compound fenobam, current clinical compounds where structures (or generic structures) are in the public domain also contain this functionality. Whether the newer chemotypes described here offer advantages to the alkyne containing compounds remains to be determined. Of particular note is that despite the diversity of chemical scaffolds that have been disclosed, where reported, the interaction of these compounds appears to be with the known allosteric (MPEP) binding site. The discovery of a second allosteric binding site and compounds that interact with it would be a notable advancement and would no doubt spur further research. In any case, the current excitement for this target and approach to new therapeutics should continue to result in new and interesting discoveries for several years to come. Hopefully, such discoveries will also soon translate into useful therapeutics for patients.

■ AUTHOR INFORMATION

Corresponding Author
Mailing address: Department of Pharmacology, Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee 37232-6600, United States. E-mail: kyle.a.emmitte@vanderbilt.edu. Telephone: 615-936-8401. Fax: 615-343-6532.

Author Contributions
K.A.E. researched the patent and primary literature, wrote the manuscript, and prepared all figures, schemes, and tables.

■ ABBREVIATIONS

7TM, seven transmembrane; Ac, acetyl; ALT, alanine transaminase; Ar, aryl; AUC, area under the curve; BINAP, 2,2′-bis-(diphenylphosphino)-1,1′-binaphthyl; BOP, benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate; CDI, carbonyldiimidazole; CHO, Chinese hamster ovary; CNS, central nervous system; dba, dibenzylideneacetone; DCC, N,N'-dicyclohexylcarbodiimide; DIEA, N,N-diisopropylethylamine; DMAP, 4-dimethylaminopyridine; DME, dimethoxyethane; DMF, N,N-dimethylformamide; DMSO, dimethyl sulfoxide; dppf, 1,1′-bis(diphenylphosphanyl) ferrocene; EDC, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide; Et, ethyl; FPS, fear-potentiated startle test; FXS, fragile X syndrome; GERD, gastresophageal reflux disease; GPCR, G-protein-coupled receptors; HATU, 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate methanaminium; HEK, human embryonic kidney; HOBt, hydroxybenzotriazole; HPLC, high performance liquid chromatography; HTS, high throughput screening; ^{i}Bu, isobutyl; IP, intraperitoneal; ^{i}Pr, isopropyl; LELP, lipophilic ligand efficiency metrics; Me, methyl; mGlu, metabotropic glutamate receptor; M-MPEP, 2-((3-methoxyphenyl)ethynyl)-6-methylpyridine; MPEP, 2-methyl-6-(phenylethynyl) pyridine; mPEPy, 3-methoxy-5-(pyridin-2-ylethynyl)pyridine; Ms, methanesulfonyl; MTEP, 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine; NAM, negative allosteric modulator; NIDA, National Institute on Drug Abuse; ^{n}Bu, n-butyl; ^{n}Pr, n-propyl; PAM, positive allosteric modulator; PCP, phencyclidine; PD, Parkinson's disease; PD-LID, Parkinson's disease levodopa-induced dyskinesia; Ph, phenyl; PI, phosphatidylinositol; PKC, protein kinase C; PPA, polyphosphoric acid; PS, polystyrene; pyBOP, (benzotriazol-1-yloxy) tripyrrolidinophosphonium hexafluorophosphate; SAR, structure—activity relationship; SIH, stress-induced hyperthermia; SILE, size independent ligand efficiency; S$_N$Ar, nucleophilic aromatic substitution; ^{t}Bu, $tert$-butyl; THF, tetrahydrofuran; Ts, $para$-toluenesulfonic acid; XANTPHOS, 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene

■ REFERENCES

(1) Schoepp, D. D., Jane, D. E., and Monn, J. A. (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors. *Neuropharmacology* 38, 1431–1476.

(2) Conn, P. J., and Pin, J.-P. (1997) Pharmacology and functions of metabotropic glutamate receptors. *Annu. Rev. Pharmacol. Toxicol.* 37, 205–237.

(3) Knöpfel, T., Kuhn, R., and Allgeier, H. (1995) Metabotropic glutamate receptors: Novel targets for drug development. *J. Med. Chem.* 38, 1417–1426.

(4) Niswender, C. M., Jones, C. K., and Conn, P. J. (2005) New therapeutic frontiers for metabotropic glutamate receptors. *Curr. Top. Med. Chem.* 5, 847–857.

(5) Ritzén, A., Mathiesen, J. M., and Thomsen, C. (2005) Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. *Basic Clin. Pharmacol. Toxicol.* 97, 202–213.

(6) Kew, J. N. C. (2004) Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential. *Pharmacol. Ther.* 104, 233–244.

(7) Gasparini, F., Lingenhöhl, K., Stoehr, N., Flor, P. J., Heinrich, M., Vranesic, I., Biollaz, M., Allgeier, H., Heckendorn, R., Urwyler, S., Varney, M. A., Johnson, E. C., Hess, S. D., Rao, S. P., Sacaan, A. I., Santori, E. M., Veliocelebi, G., and Kuhn, R. (1999) Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systematically active mGlu5 receptor antagonist. *Neuropharmacology* 38, 1493–1503.

(8) Cosford, N. D., Tehrani, L., Roppe, J., Schweiger, E., Smith, N. D., Anderson, J., Bristow, L., Brodkin, J., Jiang, X., McDonald, I., Rao, S., Washburn, M., and Varney, M. A. (2003) 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic

429

dx.doi.org/10.1021/cn2000266 |*ACS Chem. Neurosci.* 2011, 2, 411–432

glutamate subtype 5 receptor antagonist with anxiolytic activity. *J. Med. Chem. 46*, 204–206.

(9) Zhu, C. Z., Wilson, S. G., Mikusa, J. P., Wismer, C. T., Gauvin, D. M., Lynch, J. J., Wade, C. L., Decker, M. W., and Honore, P. (2004) Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities. *Eur. J. Pharmacol. 506*, 107–118.

(10) Nicolas, L. B., Kolb, Y., and Prinssen, E. P. M. (2006) A combined marble burying-locomoter activity test in mice: A practical screening test with sensitivity to different classes of anxiolytics and antidepressants. *Eur. J. Pharmacol. 547*, 106–115.

(11) Pietraszek, M., Sukhanov, I., Maciejak, P., Szyndler, J., Gravius, A., Wislowska, A., Plaznik, A., Bespalov, A. Y., and Danysz, W. (2005) Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. *Eur. J. Pharmacol. 514*, 25–34.

(12) Busse, C. S., Brodkin, J., Tattersall, D., Anderson, J. J., Warren, N., Tehrani, L., Bristow, L. J., Varney, M. A., and Cosford, N. D. P. (2004) The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety. *Neuropsychopharmacology 29*, 1971–1979.

(13) Klodzinska, A., Tatarczynska, E., Chojnacka-Wójcik, E., Nowak, G., Cosford, N. D. P., and Pilc, A. (2004) Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA$_A$ signaling. *Neuropharmacology 47*, 342–350.

(14) Spooren, W. P. J. M., Vassout, A., Neijt, H. C., Kuhn, R., Gasparini, F., Roux, S., Porsolt, R. D., and Gentsch, C. (2000) Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. *J. Pharmacol. Exp. Ther. 295*, 1267–1275.

(15) Jensen, J., Lehmann, A., Uvebrant, A., Carlsson, A., Jerndal, G., Nilsson, K., Frisby, C., Blackshaw, L. A., and Mattsson, J. P. (2005) Transient lower esophageal sphincter relaxations in dogs are inhibited by a metabotropic glutamate receptor 5 antagonist. *Eur. J. Pharmacol. 519*, 154–157.

(16) Frisby, C. L., Mattsson, J. P., Jensen, J. M., Lehmann, A., Dent, J., and Blackshaw, L. A. (2005) Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands. *Gastroenterology 129*, 995–1004.

(17) de Vrij, F. M. S., Levenga, J., van der Linde, H. C., Koekkoek, S. K., De Zeeuw, C. I., Nelson, D. L., Oostra, B. A., and Willemsen, R. (2008) Rescue of behavioral phenotype and neuronal protrusion morphology in *Fmr1* KO mice. *Neurobiol. Dis. 31*, 127–132.

(18) Yan, Q. J., Rammal, M., Tranfaglia, M., and Bauchwitz, R. P. (2005) Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. *Neuropharmacology 49*, 1053–1066.

(19) McGeehan, A. J., and Olive, M. F. (2003) The mGluR5 antagonist MPEP reduces the conditioned rewarding effects of cocaine but not other drugs of abuse. *Synapse 47*, 240–242.

(20) Chiamulera, C., Epping-Jordan, M. P., Zocchi, A., Marcon, C., Cottiny, C., Tacconi, S., Corsi, M., Orzi, F., and Conquet, F. (2001) Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. *Nat. Neurosci. 4*, 873–874.

(21) Martin-Fardon, R., Baptista, M. A. S., Dayas, C. V., and Weiss, F. (2009) Dissociation of the effects of MTEP [3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]piperidine] on conditioned reinstatement and reinforcement: Comparison between cocaine and a conventional reinforcer. *J. Pharmacol. Exp. Ther. 329*, 1084–1090.

(22) Kumaresan, V., Yuan, M., Yee, J., Famous, K. R., Anderson, S. M., Schmidt, H. D., and Pierce, R. C. (2009) Metabotropic glutamate receptor 5 (mGluR5) antagonists attenuate cocaine priming- and cue-induced reinstatement of cocaine seeking. *Behav. Brain Res. 202*, 238–244.

(23) Bäckstrom, P., and Hyytiä, P. (2006) Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine seeking. *Neuropsychopharmacology 31*, 778–786.

(24) Iso, Y., Grajkowska, E., Wroblewski, J. T., Davis, J., Goeders, N. E., Johnson, K. M., Sanker, S., Roth, B. L., Tueckmantel, W., and Kozikowski, A. P. (2006) Synthesis and structure-activity relationships of 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic glutamate receptor subtype 5 antagonists; search for cocaine medications. *J. Med. Chem. 49*, 1080–1100.

(25) Kenny, P. J., Boutrel, B., Gasparini, F., Koob, G. F., and Markou, A. (2005) Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats. *Psychopharmacology 179*, 247–254.

(26) Tessari, M., Pilla, M., Andreoli, M., Hutcheson, D. M., and Heidbreder, C. A. (2004) Antagonism at metabotropic glutamate 5 receptors inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking. *Eur. J. Pharmacol. 499*, 121–133.

(27) Platt, D. M., Rowlett, J. K., and Spealman, R. D. (2008) Attenuation of cocaine self-administration in squirrel monkeys following repeated administration of the mGluR5 antagonist MPEP: comparison with dizocilpine. *Psychopharmacology 200*, 167–176.

(28) Lee, B., Platt, D. M., Rowlett, J. K., Adewale, A. S., and Spealman, R. D. (2005) Attenuation of behavioral effects of cocaine by the metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)-pyridine in squirrel monkeys: Comparison with dizocilpine. *J. Pharmacol. Exp. Ther. 312*, 1232–1240.

(29) Tronci, V., Vronskaya, S., Montgomery, N., Mura, D., and Balfour, D. J. K. (2010) The effects of the mGluR5 receptor antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) on behavioural responses to nicotine. *Psychopharmacology 211*, 33–42.

(30) Kotlinska, J., and Bochenski, M. (2007) Comparison of the effects of mGluR1 and mGluR5 antagonists on the expression of behavioral sensitization to the locomotor effect of morphine and the morphine withdrawal jumping in mice. *Eur. J. Pharmacol. 558*, 113–118.

(31) Gass, J. T., Osborne, M. P. H., Watson, N. L., Brown, J. L., and Olive, M. F. (2009) mGluR5 antagonism attenuates methamphetamine reinforcement and prevents reinstatement of methamphetamine-seeking behavior in rats. *Neuropsychopharmacology 34*, 820–833.

(32) Adams, C. L., Short, J. L., and Lawrence, A. J. (2010) Cue-conditioned alcohol seeking in rats following abstinence: Involvement of metabotropic glutamate 5 receptors. *Br. J. Pharmacol. 159*, 534–542.

(33) Besheer, J., Grondin, J. J. M., Salling, M. C., Spanos, M., Stevenson, R. A., and Hodge, C. W. (2009) Interoceptive effects of alcohol require mGlu5 receptor activity in the nucleus accumbens. *J. Neurosci. 29*, 9582–9591.

(34) Gass, J. T., and Olive, M. F. (2009) Role of protein kinase C epsilon (PKCε) in the reduction of ethanol reinforcement due to mGluR5 antagonism in the nucleus accumbens shell. *Psychopharmacology 204*, 587–597.

(35) Schroeder, J. P., Spanos, M., Stevenson, J. R., Besheer, J., Salling, M., and Hodge, C. W. (2008) Cue-induced reinstatement of alcohol-seeking behavior is associated with increased ERK$_{1/2}$ phosphorylation in specific limbic brain regions: Blockade by the mGluR5 antagonist MPEP. *Neuropharmacology 55*, 546–554.

(36) Lominac, K. D., Kapasova, Z., Hannun, R. A., Patterson, C., Middaugh, L. D., and Szumlinski, K. K. (2006) Behavioral and neurochemical interactions between group 1 mGluR antagonists and ethanol: Potential insight into their anti-addictive properties. *Drug Alcohol Depend 85*, 142–156.

(37) Morin, N., Grégoire, L., Gomez-Mancilla, B., Gasparini, F., and Di Paolo, T. (2010) Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in Parkinsonian monkeys. *Neuropharmacology 58*, 981–986.

(38) Lindsley, C. W., and Emmitte, K. A. (2009) Recent progress in the discovery and development of negative allosteric modulators of mGluR5. *Curr. Opin. Drug Discovery Dev. 12*, 446–457.

(39) Gasparini, F., Bilbe, G., Gomez-Mancilla, B., and Spooren, W. (2008) mGluR5 antagonists: Discovery, characterization and drug development. *Curr. Opin. Drug Discovery Dev. 11*, 655–665.

(40) Jaeschke, G., Wettstein, J. G., Nordquist, R. E., and Spooren, W. (2008) mGluR5 receptor antagonists and their therapeutic potential. *Expert Opin. Ther. Pat. 18*, 123–142.

(41) Rocher, J.-P. (2010) *Discovery of novel series of selective mGluR5 negative allosteric modulators. Metabotropic glutamate receptors: Translation from discovery to clinical trials*, New York, NY, February 23, 2010; The New York Academy of Sciences, New York.

(42) Keywood, C., Wakefield, M., and Tack, J. (2009) A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastroesophageal reflux disease. *Gut 58*, 1192–1199.

(43) Marin, J. C. A., and Goadsby, P. J. (2010) Glutamatergic fine tuning with ADX-10059: A novel therapeutic approach for migraine? *Exp. Opin. Invest. Drugs 19*, 555–561.

(44) Goadsby, P. J., and Keywood, C. G. (2009) Investigation of the role of mGluR5 inhibition in migraine: A proof of concept study of ADX10059 in acute treatment of migraine. *Abstracts of Papers*, 61st annual meeting of the American Academy of Neurology, Seattle, WA, Abstract P06.006, American Academy of Neurology, Saint Paul, MN.

(45) Pecknold, J. C., McClure, D. J., Appeltauer, L., Wrzesinski, L., and Allan, T. (1982) Treatment of anxiety using fenobam (a non-benzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. *J. Clin. Psychopharmacol. 2*, 129–132.

(46) Berry-Kravis, E. M., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., Hutchinson, J., Snape, M., Tranfaglia, M., Nguyen, D. V., and Hagerman, R. (2009) A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. *J. Med. Genet. 46*, 266–271.

(47) Gasparini, F. (2009) mGluR5 antagonists as potential symptomatic therapy for Fragile X Disorder. *Abstracts of Papers*, 239th ACS national meeting, San Francisco, CA, Abstract MEDI 12031, American Chemical Society: Washingtion, DC.

(48) Berg, D., Godau, J., Trenkwalder, C., Eggert, K., Csoti, I., Storch, A., Gasparini, F., Hariry, S., Johns, D., and Gomez-Mancilla, B. (2009) A randomized, controlled trial evaluating AFQ056 in reducing levodopa-induced dyskinesia in patients with Parkinson's disease. *Abstracts of Papers*, 13th International Congress of Parkinson's Disease and Movement Disorders, Paris, France, Abstract LB-05, The Movement Disorder Society: Milwaukee, WI.

(49) Addex Pharmaceuticals: Addex ADX10059 has potential for Parkinson's disease levodopa induced dyskinesia (PD-LID). Press Release (2009) September 14.

(50) Addex Pharmaceuticals: Addex ADX48621 positive primate Parkinson's data. Press Release (2009) November 24.

(51) Addex Pharmaceuticals: Development of ADX10059 ended for long-term use. Press Release (2009) December 15.

(52) Harris, G. Promise seen in drug for retardation syndrome. (April 30, 2010) New York Times, p A1.

(53) AstraZeneca PLC: AstraZeneca Development Pipeline. Pipeline Summary (2009) July 30.

(54) F. Hoffman-LaRoche, Ltd.: Roche Pipeline 2010. Pipeline Summary (2010) April 15.

(55) Seaside Therapeutics: Novel therapies for patients with autism and Fragile X Syndrome. Corporate Fact Sheet (2010) Quarter 1.

(56) Dove, P., Granberg, K., Isaac, M., Någård, M., and Slassi, A. (2009) 1,2,4-triazole ether derivatives as modulators of mGluR5. WO 2009/054785 A1.

(57) Bratt, E., Granberg, K., Isaac, M., Någård, M., and Slassi, A. (2009) Amide linked heteroaromatic derivatives as modulators of mGluR5. WO 2009/054790 A1.

(58) Isaac, M., and Wållberg, A. (2009) Amino 1,2,4-triazole derivatives as modulators of mGluR5. WO 2009/054794 A1.

(59) Wensbo, D., Xin, T., Stefanac, T., Arora, J., Edwards, L., Isaac, M., Slassi, A., Stormann, T. M., McLeod, D. A., Kers, A., Malmberg, J., Oscarsson, K., Gyback, H., Johansson, M., Minidis, A., Waldman, M., Yngve, U., and Osterwall, C. New compounds. WO 2004/014881 A2.

(60) Granberg, K., and Wållberg, A. (2009) 1,2,4-Triazole aryl *N*-oxides derivatives as modulators of mGluR5. WO 2009/054786 A1.

(61) Bratt, E. Granberg, K. (2009) 1,2,3-Triazole pyrrolidine derivatives as modulators of mGluR5. WO 2009/054789 A1.

(62) Granberg, K., Slassi, A., Stefanac, T., and Wållberg, A. (2009) 1,2,4-Triazole carboxylic acid derivatives as modulators of mGluR5. WO 2009/054787 A1.

(63) Granberg, K., and Holm, B. (2009) Aminopyridine derivatives as modulators of mGluR5. WO 2009/054792 A1.

(64) Granberg, K., Holm, B., and Någård, M. (2009) Thiophene 1,2,4-triazole derivatives as modulators of mGluR5. WO 2009/054793 A1.

(65) Granberg, K., and Holm, B. (2009) Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mGluR5. WO 2009/054791 A1.

(66) Hansen, T. V., Wu, P., and Fokin, V. V. (2005) One-pot copper(I)-catalyzed synthesis of 3,5-disubstituted isoxazoles. *J. Org. Chem. 70*, 7761–7764.

(67) Granberg, K., and Holm, B. (2010) Sulphide bridged derivatives as modulators of mGluR5. WO 2010/123451 A1.

(68) Corey, E. J., Bakshi, R. K., and Shibata, S. (1987) Highly enantioselective borane reduction of ketones catalyzed by chiral oxazaborolidines. Mechanism and synthetic implications. *J. Am. Chem. Soc. 109*, 5551–5553.

(69) Wágner, G., Wéber, C., Nyéki, O., Nógrádi, K., Bielik, A., Molnár, L., Bobok, A., Horvath, A., Kiss, B., Kolok, S., Nagy, J., Kurkó, D., Gál, K., Greiner, I., Szombathelyi, Z., Keserü, G. M., and Domány, G. (2010) Hit to lead optimization of disubstituted oxadiazoles and tetrazoles as mGluR5 NAMs. *Bioorg. Med. Chem. Lett. 20*, 3737–3741.

(70) Gasparini, F., Andres, H., Flor, P. J., Heinrich, M., Inderbitzin, W., Lingenhöhl, K., Müller, H., Munk, V. C., Omilusik, K., Stierlin, C., Stoehr, N., Vranesic, I., and Kuhn, R. (2002) [^{3}H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5. *Bioorg. Med. Chem. Lett. 12*, 407–409.

(71) Nissink, J. W. M. (2009) Simple size-independent measure of ligand efficiency. *J. Chem. Inf. Model. 49*, 1617.

(72) Keserü, G. M., and Makara, G. M. (2009) The influence of lead discovery strategies on the properties of drug candidates. *Nat. Rev. Drug Discovery 8*, 203–212.

(73) Galambos, J., Wágner, G., Nógrádi, K., Bielik, A., Molnár, L., Bobok, A., Horváth, A., Kiss, B., Kolok, S., Nagy, J., Kurkó, Bakk, M. L., Vastag, M., Sághy, K., Gyertyán, I., Gál, K., Greiner, I., Szombathelyi, Z., Keserü, G. M., and Domány, G. (2010) Carbamoyloximes as novel noncompetitive mGlu5 receptor antagonists. *Bioorg. Med. Chem. Lett. 20*, 4371–4375.

(74) Vogel, J. R., Beer, B., and Clody, D. E. (1971) A simple and reliable conflict procedure for testing anti-anxiety agents. *Psychopharmacology 21*, 1–7.

(75) Pilla, M., Andreoli, M., Tessari, M., Delle-Fratte, S., Roth, A., Butler, S., Brown, F., Shah, P., Bettini, E., Cavallini, P., Benedetti, R., Minick, D., Smith, P., Tehan, B., D'Alessandro, P. D., Lorthioir, O., Ball, C., Garzya, V., Goodacre, C., and Watson, S. (2010) The identification of novel orally active mGluR5 antagonist GSK2210875. *Bioorg. Med. Chem. Lett. 20*, 7521–7524.

(76) Ferrari, L., Crestan, V., Sabattini, G, Vinco, F., Fontana, S., and Gozzi, A. (2010) Brain penetration of local anaesthetics in the rat: Implications for experimental neuroscience. *J. Neurosci. Methods 186*, 143–149.

(77) Njung'e, K., and Handley, S. L. (1991) Evaluation of marble-burying behavior as a model of anxiety. *Pharmacol., Biochem. Behav. 38*, 63–67.

(78) Britton, T. C., Dehlinger, V., Fivush, A. M., Hollinshead, S. P., and Vokits, B. P. (2009) 3-Indazolyl-4-pyridylisothiazoles. WO2009/123855 A1.

(79) Dallmann, R., Steinlechner, S., von Hörsten, S., and Karl, T. (2006) Stress-induced hyperthermia in the rat: Comparison of classical and novel recording methods. *Lab. Anim. 40*, 186–193.

(80) Jimenez, H. N., Li, G., Doller, D., Grenon, M., White, A. D., Guo, M., and Ma, G. (2010) Adamantyl diamide derivatives and uses of same. WO 2010/011570 A1.

(81) Cosford, N. D. P., Roppe, J., Tehrani, L., Schweiger, E. J., Seiders, T. J., Chaudary, A., Rao, S., and Varney, M. A. (2003) [^{3}H]-Methoxymethyl-MTEP and [^{3}H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. *Bioorg. Med. Chem. Lett. 13*, 351.

(82) Moore, N. A., Rees, G., Sanger, G., and Tye, N. C. (1994) Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. *Behav. Pharmacol. 5*, 196–202.

(83) Henrich, M., Weil, T., Müller, S., Nagel, J., Gravius, A., Kauss, V., Zemribo, R., and Erdmane, E. (2009) Pyrazolopyrimidines, a process for their preparation and their use as medicine. WO 2009/095254 A1.

(84) Danysz, W., Dekundy, A., Hechenberger, M., Henrich, M., Jatzke, C., Nagel, J., Parsons, C. G. R., Weil, T., Fotins, J., Gutcaits, A., Kalvinsh, I., Zemribo, R., and Kauss, V. (2008) Pyrazolopyrimidines, a process for their preparation and the use as a medicine. WO 2008/015271 A1.

(85) Kulkarni, S. S., and Newman, A. H. (2007) Design and synthesis of novel heterobiaryl amides as metabotropic glutamate receptor subtype 5 antagonists. *Bioorg. Med. Chem. Lett. 17*, 2074–2079.

(86) Kulkarni, S. S., Nightingale, B., Dersch, C. M., Rothman, R. B., and Newman, A. H. (2006) Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. *Bioorg. Med. Chem. Lett. 16*, 3371–3375.

(87) Kulkarni, S. S., Zou, M.-F., Cao, J., Deschamps, J. R., Rodriguez, A. L., Conn, P. J., and Newman, A. H. (2009) Structure—activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotrobic glutamate receptor subtype 5 antagonists. *J. Med. Chem. 52*, 3563–3575.

(88) Kulkarni, S. S., and Newman, A. H. (2007) Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonists. *Bioorg. Med. Chem. Lett. 17*, 2987–2991.

(89) Zhang, P., Zou, M.-F., Rodriguez, A. L., Conn, P. J., and Newman, A. H. (2010) Structure—activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic glutamate receptor subtype 5. *Bioorg. Med. Chem. 18*, 3026–3035.

(90) Boice, G. N., Savarin, C. G., Murry, J. A., Conrad, K., Matty, L., Corley, E. G., Smitrovich, J. H., and Hughes, D. (2004) An efficient synthesis of a highly functionalized 4-arylpiperidine. *Tetrahedron 60*, 11367–11374.

(91) Milbank, J. B. J., Knauer, C. S., Augelli-Szafran, C. E., Sakkab-Tan, A. T., Lin, K. K., Yamagata, K., Hoffman, J. K., Zhuang, N., Thomas, J., Galatsis, P., Wendt, J. A., Mickelson, J. W., Schwarz, R. D., Kinsora, J. J., Lotarski, S. M., Stakich, K., Gillespie, K. K., Lam, W. W., and Mutlib, A. E. (2007) Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. *Bioorg. Med. Chem. Lett. 17*, 4415–4418.

(92) Sharma, S., Rodriguez, A. L., Conn, P. J., and Lindsley, C. W. (2008) Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: Unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold. *Bioorg. Med. Chem. Lett. 18*, 4098–4101.

(93) Rodriguez, A. L., Nong, Y., Sekaran, N. K., Alagille, D., Tamagnan, G. D., and Conn, P. J. (2005) A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. *Mol. Pharmacol. 68*, 1793–1802.

(94) Spanka, C., Glatthar, R., Desrayaud, S., Fendt, M., Orain, D., Troxler, T., and Vranesic, I. (2010) Piperidyl amides as novel, potent and orally active mGlu5 receptor antagonists with anxiolytic-like activity. *Bioorg. Med. Chem. Lett. 20*, 184–188.

(95) Bouwknecht, J. A., Olivier, B., and Paylor, R. E. (2007) The stress-induced hyperthermia paradigm as a physiological animal model for anxiety: A review of pharmacological and genetic studies in the mouse. *Neurosci. Biobehav. Rev. 31*, 41–59.

(96) Millan, M. J., and Brocco, M. (2003) The Vogel conflict test: Procedural aspects, γ-aminobutyric acid, glutamate and monoamines. *Eur. J. Pharmacol. 463*, 67–96.

(97) Davis, M., Falls, W. A., Campeau, S., and Kim, M. (1993) Fear-potentiated startle: A neural and pharmacological analysis. *Behav. Brain Res. 58*, 175–198.

(98) Davis, M. (1986) Pharmacological and anatomical analysis of fear conditioning using the fear-potentiated startle paradigm. *Behav. Neurosci. 100*, 814–824.

(99) Carcache, D., Vranesic, I., Blanz, J., Desrayaud, S., Fendt, M., and Glatthar, R. (2011) Benzimidazoles as potent and orally active mGlu5 receptor antagonists with an improved PK profile. *ACS Med. Chem. Lett. 2*, 58–62.

(100) Hintermann, S., Vranesic, I., Allgeier, H., Brülisauer, A., Hoyer, D., Lemaire, M., Moenius, T., Urwyler, S., Whitebread, S., Gasparini, F., and Auberson, Y. (2007) ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: Identification, in vitro pharmacology, pharmacokinetic and biodistribution studies. *Bioorg. Med. Chem. 15*, 903–914.

(101) Burdi, D. F., Hunt, R., Fan, L., Hu, T., Wang, J., Guo, Z., Huang, Z., Wu, C., Hardy, L., Detheux, M., Orsini, M. A., Quinton, M. S., Lew, R., and Spear, K. (2010) Design, synthesis, and structure—activity relationships of novel bicyclic azole-amines as negative allosteric modulators of metabotropic glutamate receptors. *J. Med. Chem. 53*, 7107–7118.

(102) Rodriguez, A. L., Williams, R., Zhou, Y., Lindsley, S. R., Le, U., Grier, M. D., Weaver, C. D., Conn, P. J., and Lindsley, C. W. (2009) Discovery and SAR of novel mGluR5 non-competitive antagonists not based on an MPEP chemotype. *Bioorg. Med. Chem. Lett. 19*, 3209–3213.

(103) Felts, A. S., Saleh, S. A., Le, U., Rodriguez, A. L., Weaver, C. D., Conn, P. J., Lindsley, C. W., and Emmitte, K. A. (2009) Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu$_5$. *Bioorg. Med. Chem. Lett. 19*, 6623–6626.

(104) Shipe, W. D., Wolkenberg, S. E., and Lindsley, C. W. (2005) Accelerating lead development by microwave-enhanced medicinal chemistry. *Drug Discovery Today: Technol. 2*, 155.

(105) Zhou, Y., Rodriguez, A. L., Williams, R., Weaver, C. D., Conn, P. J., and Lindsley, C. W. (2009) Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTS. *Bioorg. Med. Chem. Lett. 19*, 6502–6506.

(106) Rodriguez, A. L., Grier, M. D., Jones, C. K., Herman, E. J., Kane, A. S., Smith, R. L., Williams, R., Zhou, Y., Marlo, J. E., Days, E. L., Blatt, T. N., Jadhav, S., Menon, U. N., Vinson, P. N., Rook, J. M., Stauffer, S. R., Niswender, C. M., Lindsley, C. W., Weaver, C. D., and Conn, P. J. (2010) Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. *Mol. Pharmacol. 78*, 1105–1123.

(107) Van Wagenen, B. C., Stormann, T. M., Moe, S. T., Sheehan, S. M., McLeod, D. A., Smith, D. L., Isaac, M. B., Slassi, A. (2001) Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists. WO 01/12627 A1.

(108) Felts, A. S., Lindsley, S. R., Lamb, J. P., Rodriguez, A. L., Menon, U. N., Jadhav, S., Jones, C. K., Conn, P. J., Lindsley, C. W., and Emmitte, K. A. (2010) 3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu$_5$: Identification of easily prepared tool compounds with CNS exposure in rats. *Bioorg. Med. Chem. Lett. 20*, 4390–4394.